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1.1 Background and aim of the work  
 
The atrial natriuretic peptide, ANP, was the first described member of the natriuretic 
peptide family, a family of cardiovascular cyclic peptide hormones. Due to its 
natriuretic and diuretic properties ANP exhibits strong cardiovascular effects, such as 
regulation of blood pressure and plasma volume expansion (Levin et al. 1998). 
ANP mediates most of its cardiovascular and renal effects through interaction with the 
guanylyl-cyclase-coupled natriuretic peptide receptor, NPR-A, via cGMP as second 
messenger (Levin et al. 1998). ANP also binds to the non-guanylyl-cyclase-linked 
natriuretic peptide clearance receptor (NPR-C) (Levin 1993). Besides the clearance 
function exerted by NPR-C, an NPR-C-mediated inhibition of adenylyl-cyclase was 
shown to be responsible for several in vitro effects of ANP.  
In the last years natriuretic peptides and their receptors have been demonstrated to be 
expressed in diverse tissues besides the cardiovascular and renal system. In this 
context, ANP and its receptors were shown to be expressed in thymus (Vollmar and 
Schulz 1990a), as well as in macrophages (Vollmar and Schulz 1994; Vollmar and 
Schulz 1995; Kiemer and Vollmar 1997). ANP was therefore suggested to be a 
modulator of immune functions. In fact ANP was shown to attenuate the induction of 
inflammatory mediators, such as cyclooxygenase-2 (Kiemer et al. 2002b) and TNF-α 
(Kiemer et al. 2000a; Tsukagoshi et al. 2001). The latter was demonstrated in LPS-
stimulated macrophages (Kiemer et al. 2000a) as well as in reperfused livers (Kiemer 
et al. 2000b). These observations provide novel aspects in the biological profile of NP 
by demonstrating a relationship of ANP to the immune system. In this context it was 
determined whether ANP may not only inhibit the production of proinflammatory 
factors like TNF-α, but also their effects on vascular cells. TNF-α represents an 
important proinflammatory cytokine, known to play a crucial role in the pathogenesis 
of several inflammatory diseases, such as atherosclerosis, septic shock or rheumatoid 
arthritis (De Martin et al. 2000). It is mainly produced by activated monocytes and 
macrophages and influences the growth and behaviour of endothelial cells, monocytes, 
and smooth muscle cells (Heller and Kronke 1994). Inflammatory conditions, such as 
atherosclerosis, or septic shock, are closely related to the increased infiltration of 
leukocytes into inflamed tissue (Gimbrone, Jr. et al. 1997). Central pathomechanisms 
of TNF-α-induced inflammatory reactions involve the induction of endothelial cell 
adhesion molecules and increased endothelial cell leakiness, whereby formation of 
intercellular gaps in vascular endothelium is regarded as one of the initial mechanisms 
contributing to the development of an atheromatous plaque (Raines and Ross 1995). 
Aim of this work was to clarify whether ANP is able to protect human umbilical vein 
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endothelial cells against TNF-α-induced expression of adhesion molecules and 
changes in endothelial cytoskeleton. 
 
Concerning these two issues the following questions had to be answered: 
 
1. Increased endothelial cell adhesion molecule (CAM) expression: 
a) Does ANP influence TNF-α-induced adhesion molecule expression in 
HUVEC? 
b) Which receptor is responsible for the observed inhibitory properties of ANP on 
TNF-α-induced adhesion molecule expression? 
c) Does ANP affect the activation of the proinflammatory transcription factor NF-
κB? 
d) What is the molecular mechanism of the inhibitiory action of ANP on TNF-α-
induced NF-κB DNA binding activity? 
e) Does ANP influence other TNF-α-activated transcription factors? Characteri-
zation of the effects of ANP on AP-1. 
 
2. Endothelial cytoskeleton changes: 
a) Does ANP influence TNF-α-induced permeability and cytoskeleton changes? 
b) What is the molecular mechanism of the inhibitiory action of ANP on TNF-α-
induced permeability and cytoskeleton changes? 
a. Does ANP inhibit stress fiber formation in endothelial cells? 
b. Does ANP affect actin polymerization? 
c. Does ANP influence p38 MAPK? 
d. What are the pathways responsible for ANP mediated p38 MAPK 
inhibition? 
e. Does there exist a causal relationship between p38 MAPK and the actin 
cytoskeleton? 
 
3. Does ANP influence TNF-α-induced MCP-1 expression? 
a) Does ANP influence TNF-α-induced MCP-1 expression in HUVEC? 
b) Which receptor is responsible for the observed inhibitory properties of ANP on 
TNF-α-induced MCP-1 expression? 
c) Does there exist a causal relationship between MKP-1-induced p38 MAPK 
inactivation and inhibition of MCP-1 expression by ANP? 
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1.2 The natriuretic peptides 
 
1.2.1 History 
 
It is now more than 20 years ago that de Bold and coworkers observed a massive 
natriuresis and diuresis after infusion of an atrial tissue extract into rats. This 
observation led to the isolation and cloning of the first member of a group of 
cardiovascular natriuretic peptides, the atrial natriuretic peptide, ANP (de Bold et al. 
1981). Only a few years later a structure homologue of ANP was isolated from porcine 
brain homogenates and therefore named brain natriuretic peptide, BNP (Sudoh et al. 
1988). After BNP, a second natriuretic peptide was isolated from the porcine brain. In 
analogy after ANP and BNP it was called CNP, C-type natriuretic peptide (Sudoh et 
al. 1990). Besides ANP, BNP, and CNP Urodilatin has been described as another 
member of the natriuretic peptide family (Schulz-Knappe et al. 1988, Forssmann et al. 
2001; Schermuly et al. 2001). Urodilatin was isolated from the human kidney (Schulz-
Knappe et al. 1988). Together these peptides constitute the family of natriuretic 
peptides.  
 
1.2.2 Structure of the natriuretic peptides 
 
Human ANP is a 28 amino acid peptide, whereas BNP contains 32 amino acids and 
CNP only 22. All three natriuretic peptides contain a 17 amino acid ring system as 
structural characteristic. The disulfide linkage between the two cysteine residues was 
found to be essential for the pharmacological activity of the natriuretic peptides 
(Inagami et al. 1984). Within the cyclic structure the three peptides are highly 
homologous, whereby eleven amino acids are identical for all three NP. Differences in 
structure refer to the different numbers of amino acids at the C- and N- termini of the 
peptide (figure 1). 
 
ANP: The 28 amino acid ANP differs only in six amino acids in the ring structure 
from BNP. ANP sequence is found homologous in most species. Only one amino acid 
is variable, which is methionin for e.g. in humans, dogs, pigs, sheep, whereas in 
rodents (rats, mice, rabbits) it is isoleucine. 
BNP is only 59% sequence homologous between the different species (Rosenzweig 
and Seidman 1991). 
INTRODUCTION 
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CNP structure is mostly different from ANP and BNP, because it ends after only 22 
amino acids at the C-terminus after the last cysteine in the cyclic stucture (Rosenzweig 
and Seidman 1991). 
Urodilatin is a peptide which is produced by the kidney and that could be identified 
from human urine. The only difference to ANP are four additional amino acids at the 
N-terminus of the peptide (Schulz-Knappe et al. 1988).  
 
 
figure 1: amino acid sequence of the natriuretic peptides ANP, BNP, CNP, and Urodilatin     
 (common sequences are shadded black) 
 
1.2.3 Distribution of the natriuretic peptides 
 
Highest concentrations of ANP are expressed in the left atrium, followed by the right 
atrium, the right ventricle, and finally the left ventricle in adult humans (Venugopal 
2001). More than 1% of the atrial mRNA codes for ANP (Venugopal 2001). Besides 
the heart, ANP is found in lower concentrations in tissues of the lung, the brain, the 
kidney, the adrenals, the gastrointestinal tract, the thymus (Vollmar and Schulz 
1990b), and the eye (Salzmann et al. 1998). 
The second natriuretic peptide, BNP, is predominatly distributed in the ventricles of 
the heart, followed by the brain of human adults (Venugopal 2001). As mentioned 
above, CNP is predominantly found in the brain (Stingo et al. 1992a), but also in the 
myocardial tissue (Venugopal 2001) and it was shown to be produced in peripheral 
tissues and cells, such as vascular endothelial cells (Stingo et al. 1992b).  
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1.2.4 Synthesis of the natriuretic peptides 
 
The synthesis of ANP is typical for the synthesis of peptide hormones and may serve 
as an example for the biological synthesis of the three natriuretic peptides. The main 
synthesis of ANP occurs in the heart, where ANP mRNA codes for a 152 amino acid 
peptide named prepro-ANP. After cleavage of the N-terminal signal peptide pro-ANP, 
a 126 amino acid peptide is stored in atrial granula (Rosenzweig and Seidman 1991). 
Certain stimuli, like dilation of the atrium, lead to the cleavage of pro-ANP into the N-
terminal fragment, ANP (1-98), and the biological active ANP (99-126), hereafter 
named ANP (Rosenzweig and Seidman 1991). The release of ANP from atrial 
myocytes into the circulation is mediated by exocytosis (Dagnino et al. 1991). 
 
1.2.5 The NP receptors and their signaling 
 
After the discovery of the natriuretic peptides and their diuretic and natriuretic effects, 
the question came up how these effects are mediated. It was first observed that 
injection of ANP leads to the release of cyclic guanosine-3´,5´-monophosphate (Cantin 
et al. 1984). Two years later cGMP was shown to act as a second messenger for ANP 
mediated effects (Leitman and Murad 1986). Kuno and coworkers showed that two 
different ANP-binding proteins exist, and that only binding to one of those leads to the 
release of cGMP (Leitman et al. 1986). The non-guanylyl-cyclase-coupled NP 
receptor, named NPR-C was identified in 1987 by Maack and coworkers as a 
clearence receptor. In 1989 Schulz and coworkers demonstrated by cDNA sequencing, 
that there exist two guanylyl-cyclase-coupled natriuretic peptide receptors (NPR-A 
and NPR-B, figure 2). 
The two guanylyl-cyclase-coupled NPR (size 120-140 kDa) are composed of an 
extracellular binding site, a single membrane-spanning region, and an intracellular 
tail, composed of a protein kinase like domain and a guanylyl-cyclase-like domain 
(figure 2). NPR-C (size 60 kDa), the most prevalent of the NPR, has a similar 
extracellular ligand binding site, but only a short intracellular tail of 37 amino acids 
(figure 2). Since the amino acid sequence homology in the extracellular binding 
domain is only 30-40% (Cohen et al. 1996), the three receptors show different ligand 
specificity. The NPR-A binds with high affinity ANP and BNP compared to CNP. 
Concerning the induction of cGMP release, ANP is 10-fold more potent than 
equimolar amounts of BNP. CNP is a specific ligand for NPR-B (Suga et al. 1992). 
The ligand selectivity of the clearence receptor is much lower than the specificity of 
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the other receptors and it binds the natriuretic peptides in the following order of 
affinity ANP>CNP>BNP.  
 
figure 2: schematic illustration of the three natriuretic peptide receptors: NPR-A, -B, -C 
 
As mentioned above the two guanylyl-cyclase-coupled receptors (NPR-A and NPR-B) 
contain a guanylyl-cyclase (GC)-like domain as well as a kinase-like domain. It was 
shown that after deletion of the kinase-like domain, the GC like-domain is still active, 
suggesting an inhibitory action of the kinase-like domain on the GC-activity until ANP 
binds to the extracellular domain of the receptor (Chinkers and Garbers 1989). Ligand 
binding to the extracellular site of NPR-A and NPR-B allosterically regulates changes 
in the specific activity of the cytoplasmic domain of these receptors. Another aspect 
involved in activation of the GC seems to be the dimerisation of the intracellular 
domain of the receptor (Chinkers and Wilson 1992). Subsequently the intracellular tail 
of NPR-A and NPR-B catalyses the conversion of guanosine triphosphate to cyclic 
guanosine-3´,5´-monophosphate, which functions as a second messenger in the 
following signaling cascade (Leitman and Murad 1986). 
The NPR-C mainly acts as a clearence receptor but several studies suggest an 
interaction of this receptor with two further signal transduction pathways: It was 
demonstrated that the NPR-C is able to inhibit adenylyl-cyclase (Savoie et al. 1995), 
and moreover that NPR-C specific analogues of ANP can stimulate the 
cell membrane
NPR-A NPR-B NPR-C
protein kinase 
domain
guanylyl 
cyclase 
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≅ 440 amino acids
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phospholipase C in a process that involves G-proteins (Levin 1993). These 
observations may reflect a potential involvement of the NPR-C in adenylyl-cyclase-
dependent and protein kinase C-mediated effects. 
 
1.2.6 Antiinflammatory potential of ANP 
 
After the discovery of natriuretic peptides, the hormones were thought to possess 
overall strong cardiovascular effects, such as regulation of blood pressure and plasma 
volume expansion (Levin et al. 1998). 
Interestingly, in the last years natriuretic peptides and their receptors were found to be 
expressed in diverse tissues besides the cardiovascular and renal system. Vollmar and 
coworkers were able to show that ANP and its receptors are expressed in thymus 
(Vollmar and Schulz 1990a), as well as in macrophages (Vollmar and Schulz 1994; 
Vollmar and Schulz 1995, Kiemer and Vollmar 1997). It could be demonstrated that 
ANP inhibits thymocyte proliferation and thymopoesis (Vollmar et al. 1996; Vollmar 
1997). Moreover, ANP seems to provide antiinflammatory action since it was shown 
to attenuate the induction of the inducible nitric oxide synthase (iNOS), a central 
proinflammatory enzyme, in an autocrine fashion (Kiemer and Vollmar 1997; Kiemer 
and Vollmar 1998; Kiemer and Vollmar 2001a; Kiemer and Vollmar 2001b). 
Additionally, ANP was found to attenuate the induction of other inflammatory 
mediators, such as cyclooxygenase-2 (Kiemer et al. 2002b) and TNF-α (Kiemer et al. 
2000a; Tsukagoshi et al. 2001). The inhibitory action of ANP on the inflammatory 
mediator TNF-α could also be observed in LPS-stimulated macrophages (Kiemer et al. 
2000a) as well as in reperfused livers (Kiemer et al. 2000b). Another interesting aspect 
to be mentioned is that ANP is able to induce the heat shock protein HSP70 in rat 
livers (Kiemer et al. 2002a) providing a cytoprotective potential of this natriuretic 
peptide. 
The summary of these results of the last years demonstrate a relationship of ANP to 
the immune system, thereby providing novel aspects in the biological profile of NP. 
The present work indeed deals with the antiinflammatory and antiatherogenic potential 
of this cardiovascular peptide hormone. 
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1.3 Tumor necrosis factor  
 
1.3.1 Overview 
 
Tumor necrosis factor (TNF-α) is a serum glycoprotein with a molecular weight of 
70 kDa. As an inducible proinflammatory cytokine TNF-α is mainly produced by 
activated monocytes and macrophages and influences the growth and behaviour of 
endothelial cells, monocytes, and smooth muscle cells (Heller and Kronke 1994). 
TNF-α plays a key role in mediating many inflammatory diseases such as 
atherosclerosis, septic shock, or rheumatoid arthritis (De Martin et al. 2000). 
TNF-α enhances activation of T-cells, and induces proliferation of T-cells and B-cells. 
Tumor necrosis factor attracts macrophages and granulocytes to sites of inflammation. 
This attraction stimulates further macrophages and other immune cells to release tissue 
damaging, oxygen containing substances and prostaglandins to promote further 
inflammation.  
 
1.3.2 Signal transduction by TNF-α 
 
The intracellular pathways that are activated in response to TNF-α have been 
elucidated increasingly. Many of these pathways have been demonstrated to be cell 
type-specific. In this context the endothelium has been shown to be a major target of 
proinflammatory cytokines such as TNF-α.  
The signaling pathway that couples TNF receptor activation to functional responses in 
immune defense have remained elusive. In some cells TNF-α is able to activate RAF 
kinase, initiating the ERK-MAPK pathway, while in other cells it activates parallel 
cascades, like MEK kinase, which induces p38 MAPK and JNK MAPK cell response. 
One of the probably most central responses upon TNF-α treatment is the binding of 
TNF-α to the TNFR-1 receptor of endothelial cells and subsequently the rapid 
translocation of the proinflammatory transcription factor NF-κB from the cytoplasm to 
the nucleus, where it promotes the transcription of respective genes (Karin 1999). 
These include the genes for adhesion molecules ICAM-1 (intercellular adhesion 
molecule-1), VCAM-1 (vascular cell adhesion molecule-1), E-selectin (endothelial 
leukocyte adhesion molecule-1) (for details see chapter 1.4.5), and chemokines like 
MCP-1 (monocytes chemoattractant protein-1) (see chapter 1.5).  
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1.3.3 Effects of TNF-α on endothelial cells 
 
Effects of TNF-α on endothelial cells, which represent one potential target of this 
cytokine, include protein synthesis-independent changes in cell shape and motility. 
TNF-α increases endothelial cell leakiness. Increased vascular permeability (see 
chapter 1.6) is commonly attributed to the reorganization of F-actin filaments followed 
by contraction of cells and formation of intercellular gaps (Lum and Malik 1996). In 
this context formation of intercellular gaps in vascular endothelium is regarded as one 
of the initial conditions contributing to the development of an atheromatous plaque      
(Brett et al. 1989; van Hinsbergh 1997, Wojciak-Stothard et al. 1998) 
Additionally TNF-α increases the expression of proteins that may subsequently 
regulate other cell functions such as leukocyte adhesion e.g. E-selectin, ICAM-1, 
VCAM-1, leukocyte activation (e.g. chemokines like IL-8 and MCP-1), and leukocyte 
coagulation (e.g. tissue factor and PAI-1). In health, the luminal endothelial cell 
surface is a relatively nonadhesive conduit for the cellular and macromolecular 
constituents of the blood. During inflammatory processes, like after TNF-α 
stimulation, various adhesive interactions between endothelial cells and the 
constituents of the blood are changed in order to recruit circulating leukocytes to sites 
of inflammation. The adhesive properties of the endothelium therefore play a central 
role in this pathophysiological situation. 
 
1.4 Adhesion molecules 
 
Besides transcription independent effects on endothelial cells TNF-α can modulate the 
adhesive properties of the endothelium by inducing the expression of cellular adhesion 
molecules. 
Under healthy conditions, the communication between leukocytes and cells of the 
blood tissue barrier is well regulated in order to guarantee an efficient immune 
response upon invasion of pathogens. Two pathways exist which regulate this cell to 
cell communication system. In one case the communication is mediated by different 
soluble factors such as cytokines, in the other case the interaction between cells occurs 
via intimate cell-cell contact. The latter is mediated by a group of cell surface proteins, 
so called cell adhesion molecules (CAM). The following chapter will give an overview 
of these cell adhesion molecules in order to clarify the complex interactions between 
endothelial cells and leukocytes during inflammatory situations and diseases. 
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1.4.1 Functions of cell adhesion molecules 
 
The recruitment of leukocytes to sites of inflammation is very critical for the 
inflammatory response and the repair of damaged tissue. On the one hand this 
recruitment of leukocytes can be very important for the defense against many 
pathogens, on the other hand an immoderately proceeded extravasation of leukocytes 
leads in consequence to inflammation. The process of leukocyte infiltration into the 
inflamed tissue involves several steps that are resumed in figure 3. First, the 
leukocytes transiently roll along the vessel wall. The rolling leukocytes then become 
activated by several factors released by the endothelial cell lining, such as chemokines 
and cytokines. Rolling of leukocytes is followed by a firm adhesion (sticking) to the 
vessel wall. In the last step the leukocytes transmigrate through the endothelium to 
sites of inflammation (diapedesis) (figure 3) (Aplin et al. 1998). These complex 
mechanisms are mediated by different transmembrane glycoproteins, the cell adhesion 
molecules (CAM). The initial rolling interactions are mediated by the selectins, while 
firm adhesion and diapedesis (figure 3) appear to be mediated by the interaction of 
integrins, present on the cell surface of leukocytes, with immunoglobulin gene 
superfamily members, such as ICAM-1, VCAM-1, and PECAM-1 (platelet endothelial 
cell adhesion molecule) expressed on endothelial cells (figure 3). 
 figure 3: recruitment of leukocytes to sites of inflammation 
Mac-1= macrophage glycoprotein associated with complement receptor function; LFA-1= lymphocyte 
function associated molecule, ICAM-1= intercellular cell adhesion molecule-1, VCAM-1= vascular 
neutrophil 
granulocyte
endothelial cells
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cell adhesion molecule-1, PECAM-1= platelet endothelial cell adhesion molecule-1, E-selectin= 
endothelial leukocyte adhesion molecule-1, L-selectin= leukocyte adhesion molecule, P-selectin= 
platelet activation dependent granule-external membrane protein 
 
Under inflammatory conditions, such as atherosclerosis, the expression of cell 
adhesion molecules on endothelial cells as well as on leukocytes is dynamically 
upregulated by different soluble chemokines (MCP-1, IL-1β) released by the 
endothelium. These chemokines give the driving force to the proceeding of the 
inflammation by forming chemokine gradients over the endothelium which are 
critically involved in the initial steps of leukocyte recruitment and subsequent 
transmigration. 
In this context TNF-α can act as a proinflammatory cytokine by inducing adhesion 
molecule expression that bind leukocytes to endothelial cells. The regulation of CAM 
expression occurs at the transcriptional level and is mediated, especially for ICAM-1 
and E-selectin, via the proinflammatory transcription factor NF-κB (Collins et al. 
1995).  
 
1.4.2 Classification 
 
According to their biochemical structure the cell adhesion molecules are classified in 
four groups: the immunoglobulin-like adhesion molecules, the selectins, the integrins, 
and the cadherins. The following section will concentrate on the immunoglobulin-like 
cell adhesion molecules (ICAM-1 and VCAM-1) and selectins (E-selectin) because 
these endothelial CAM are mainly involved in mediating the recruitment of leukocytes 
to the inflamed tissue. Their expression can be modified by diverse stimuli produced 
by the inflamed tissue, like TNF-α. 
 
1.4.3 Immunoglobulin-like adhesion molecules  
 
The immunoglobulin gene superfamily is one of the biggest superfamilies of cell 
adhesion molecules. This family consists of a variety of different cell-surface 
glycoproteins which are characterized by one or more immunoglobulin homology 
units (figure 4A). These immunoglobulin domains are composed of 70-100 amino acid 
residues, which are organized into two parallel β-sheets (Aplin et al. 1998) stabilized 
by a disulfide binding bridge (figure 4A). More than 70 members are known, including 
the T-cell receptor, immunoglobulins, MHC antigens, CD2, CD3, CD4, CD8, NCAM 
(neutral cell adhesion molecule), ICAM-1-5, VCAM-1, and PECAM-1. 
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The immunoglobulin-like adhesion molecules are involved in a variety of cell 
functions like antigen recognition (mediated by CD4, CD8, T-cell receptor), cell 
adhesion (mediated by NCAM linkage to an integrine e.g. LFA, lymphocyte function 
associated molecule), and leukocyte diapedesis as described above (mediated by 
ICAM-1-3, VCAM-1, and PECAM-1) (Aplin et al. 1998; Menger and Vollmar 1996). 
figure 4A: schematic illustration of the structure of immunoglobulin- 
like adhesion molecules 
 
ICAM-1= intercellular adhesion molecule-1, PECAM-1= platelet endothelial  
cell adhesion molecule-1, VCAM-1= vascular cell adhesion molecule-1  
 
ICAM-1 is a transmembrane glycoprotein consisting of five immunoglobulin 
consensus repeats (figure 4A). Under normal conditions this CAM is present on 
endothelial cells only at very low levels. Upon proinflammatory stimuli (TNF-α, 
IFN-γ, IL-1β) it is dramatically upregulated by a de novo synthesis. The characteristic 
function of ICAM-1 is the mediation of leukocyte-endothelial interaction by binding to 
certain integrins like LFA-1 and MAC-1 (figure 3) (Marlin and Springer 1987, 
Diamond et al. 1991, Aplin et al. 1998) (see under 1.4.1.). 
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ICAM-2, containing only two extracellular immunoglobulin domains, is homologous 
to ICAM-1, and is constitutively expressed on endothelial cells, platelets, monocytes, 
and some lymphocytes (Menger and Vollmar 1996). Unlike ICAM-1, ICAM-2 is not 
upregulated by proinflammatory cytokines. ICAM-2 as well as ICAM-1 mediate the 
leukocyte-endothelial interaction by binding to certain integrins.  
VCAM-1 is described as a transmembrane protein consisting of six immunoglobulin 
repeats. The protein is formed after cleavage of a seven immunoglobulin VCAM-1 
which is expressed on activated human endothelial cells (Hession et al. 1991). VCAM-
1 is upregulated by inflammatory stimuli like TNF-α, IFN-γ and IL-1β. It is involved 
in the adhesion of monocytes, lymphocytes, and eosinophiles to the vascular 
endothelium by binding to integrins (Elices et al. 1990; Bevilacqua 1993, Berlin et al. 
1995). 
PECAM-1 contains six immunoglobulin-like repeats (figure 4A) and is therefore 
structurally homologous to other cell adhesion molecules like the described ICAM-1-2 
or VCAM-1. The expression of PECAM is constitutive and is not influenced by 
stimulation with TNF-α, INF-γ, or IL-1β. It is mainly expressed at intercellular 
junctions of endothelial cells (Albelda et al. 1991). PECAM-1 is suggested to play a 
key role in regulating the endothelial integrity and in consequence the transendothelial 
migration of leukocytes (Bevilacqua 1993). 
 
1.4.4 Selectins  
 
The selectins are the smallest of the four subclasses of adhesion molecules. They are 
represented by three members: E-, P-, and L-selectin (figure 4B). The selectins are 
composed of three different protein domains. The extracellular domain is characterized 
by an amino-terminal calcium dependent lectin domain (L), an epidermal growth 
factor-like (EGF-like) domain, and two to nine short consensus repeat units, which are 
highly homologous to known repeats of complement binding proteins (figure 4B) 
(Menger and Vollmar 1996). The transmembrane region is followed by a short 
cytoplasmatic tail. 
The selectins are mainly involved in mediating the initial step of leukocyte infiltration 
in the inflamed tissue as described under 1.4.1. They mediate the transient rolling of 
leukocytes along the vessel wall as shown in figure 3. Different from most other cell 
adhesion molecules the selectins do not only bind glycoproteins, but carbohydrates, 
like sialyl Lewisx, or structures closely related to this carbohydrate compound. 
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figure 4B: schematic illustration of the structure of the selectins 
 
EGF= endothelial growth factor, L= lectin like domain, C= consensus  
repeats 
 
L-selectin (CD62L) is mainly expressed by leukocytes and only consists of two 
consensus repeats (figure 4B). L-selectin mediates the initial binding of lymphocytes, 
neutrophiles, and monocytes during rolling (figure 3) (Springer 1994). Several 
different ligands for L-selectin have been identified, of which the following three 
glycosylated mucin-like proteins are the most important: CD34, MAdCAM-1, and 
glycosylation dependent CAM-1. 
E-selectin (CD62E) consists of six complement regulatory protein regions (figure 4B). 
E-selectin is mainly expressed by the vascular endothelium and its expression is 
rapidly upregulated by proinflammatory compounds such as TNF-α, IFN-γ, and IL-1β 
(Tedder et al. 1995). E-selectin is known to bind two different carbohydrate ligands, 
the E-selectin-1 ligand and in some cases also the P-selectin glycoprotein ligand 
(PSGL)-1 (Vachino et al. 1995). E-selectin mainly functions by mediating the transient 
rolling of leukocytes as described under 1.4.1. 
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P-selectin, the platelet activation dependent granule-external membrane protein, 
(CD62P), is the biggest of the three selectins. It is charcterized by nine consensus 
complement regulatory protein domains (figure 4B), and is mainly expressed by 
platelets and the vascular endothelium (Tedder et al. 1995). Under normal conditions it 
is stored in Weibel-Palade bodies of endothelial cells or in the granules of platelets. 
Upon stimulation with certain inflammatory stimuli like thrombin, histamine, 
complement, and cytokines it is released within minutes to the cell surface of 
endothelial cells and platelets. P-selectin binds to the P-selectin glycoprotein ligand 
(PSGL)-1 on leukocytes (Vachino et al. 1995) and induces the leukocyte rolling under 
healthy and inflamed conditions. 
 
1.4.5 Transcriptional regulation of CAM by nuclear factor κB 
(NF-κB) 
 
The TNF-α-induced increase of CAM expression occurs at the transcriptional level 
and is regulated, especially for ICAM-1 and E-selectin, via the proinflammatory 
transcription factor NF-κB (Collins et al. 1995). The regulation of VCAM-1 has 
previously been shown to be mediated via pathways that include other transcription 
factors besides NF-κB (Lawson et al. 1999). The regulatory regions of the VCAM-1 
gene are composed of multiple binding elements, which are recognized by a large 
number of transcription factors. The cytokine-induced transcriptional enhancer in the 
VCAM-1 promoter requires combinatorial interactions of NF-κB with other nuclear 
activators, such as stimulatory protein-1, interferon regulatory factor-1, and activator 
protein-1 (Neish et al. 1995a). 
NF-κB was identified more than a decade ago by Sen and Baltimore as an enhancer-
binding protein controlling Igκ-light chain gene expression in B-cells (Sen and 
Baltimore 1986). Expression of NF-κB was long time thought to be restricted to B-
cells. In the following years it became evident that NF-κB is not only present in B-
cells, but also in diverse other immune cells, for example T-cells with latent 
immunodeficiency virus (HIV) have been shown to express NF-κB (McKay and 
Cidlowski 1999). To date NF-κB is known as a ubiquitously expressed transcription 
factor that can be activated in a wide variety of cells by various stimuli, such as TNF-
α, bacterial lipopolysaccharide, and IL-1 (McKay and Cidlowski 1999). NF-κB 
functions as a dimeric DNA-binding protein that consists of different subunits of a 
family of related proteins called the Rel family of transcriptional activators. The Rel 
family includes the mammalian proteins p65 (Rel A), Rel B, c-Rel, p50/p105, 
p100/p52, and the drosophila melanogaster proteins Drosal and Dif. These various 
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members of the Rel family are able to homodimerize or heterodimerize with different 
other Rel proteins. In consequence, different competent DNA-binding NF-κB factors 
with different sequence specificity are formed upon stimulation (McKay and 
Cidlowski 1999).  
In unstimulated cells, the predominant form of NF-κB is present in the cytoplasm as a 
heterodimer of p50 and p65 subunits complexed with inhibitory IκB proteins, existing 
as IκB-α, IκB-β, and IκB-ε isoforms. After cell stimulation, IκBs are phosphorylated, 
ubiquitinylated, and degraded via the 26S ribosome (figure 5). In consequence the 
classical activated form of NF-κB, the p50/p65 heterodimer, is released and can 
translocate to the nucleus where it promotes the transcription of respective genes 
(Karin 1999) (figure 5). 
figure 5: diagram of the signal transduction pathway of TNF-α- 
    activated gene transcription (ICAM-1 and E-selectin) 
 
Several reporter gene studies using deleted or substituted NF-κB binding sites reflect 
the importance of this transcription factor for the expression of proinflammatory 
proteins, including ICAM-1, VCAM-1, E-selectin, IL-1, IL-6, IL-8, COX-2, iNOS, 
and IκB-α.  
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1.5 Monocyte chemoattractant protein (MCP-1) 
 
Upon treatment of endothelial cells with proinflammatory cytokines such as TNF-α, 
endothelial cells express certain chemokines, that allow them to communicate with 
other cells (see 1.4.1). One of the most important chemokines which has been shown 
to be critically involved in the recruitment of leukocytes to sites of inflamed tissue, is 
the monocyte chemoattractant protein-1 (MCP-1) (Robinson et al. 1989). MCP-1 has 
been shown to be mainly regulated via the proinflammatory transcription factor 
NF-κB (Goebeler et al. 1999; Denk et al. 2001; Goebeler et al. 2001). Moreover, it has 
been demonstrated that the p38 MAPK and its upstream kinase MKK6 (for details see 
chapter 1.5.4) play a crucial role in the transcriptional regulation of this chemokine 
after treatment of human endothelial cells with TNF-α (Goebeler et al. 1999). 
Chemokines are also termed chemotactic cytokines according to their ability to exert 
chemoattractive activity on monocytes and T-lymphocytes (Goebeler et al. 2001). 
These soluble factors represent a large family of structurally related small molecular 
weight proteins (8-10 kDa). According to the first four conserved cysteines the 
chemokines can be classified into four groups. MCP-1 is a member of the largest 
group of chemokines, the CC chemokines (Baggiolini 1998; Luster 1998; Wang et al. 
1998). The nomenclature CC derives from the fact that the first two cysteines of the 
protein are adjacent. In the second subfamily of chemokines, the two first cysteines of 
the protein are separated by one amino acid residue (X), therefore they are termed 
CXC chemokines. A prominent member of this subfamily is IL-8 (Baggiolini et al. 
1989). Yet only one CX3C chemokine, the fractalkine (Bazan et al. 1997), has been 
identified (Reape and Groot 1999). In the structure of fractalkine the first two cysteins 
are separated by three amino acids (X), explaining the name CX3C chemokine. 
The biological activities of these chemokines are mediated by specific seven- 
transmembrane-domain G-protein coupled receptors, that are located on the surface of 
specific cells. Nine receptors for CC chemokines and five receptors for CXC 
chemokines have been identified and cloned (Reape and Groot 1999). It is well 
established that chemokine receptors accept more than one chemokine as ligand and 
that one chemokine can interact with several chemokine receptors (Reape and Groot 
1999). It has been demonstrated that CXC chemokines mainly affect neutrophiles 
while CC chemokines have been shown to interact mainly with monocytes, T- and B-
lymphocytes. The fact that a complex network of interactions of chemokines with 
different receptors and different cell types exists, reflects the crucial role of these 
inflammatory mediators in regulating the cellular immune response upon treatment 
with TNF-α or other proinflammatory stimuli. In the last years it has become evident 
that the expression of chemokine receptors is not restricted to leukocytes since they are 
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also present on endothelial cells (Gupta et al. 1998; Volin et al. 1998) and vascular 
smooth muscle cells (Hayes et al. 1998). 
Most chemokines have a heparin-binding site which can interact with several 
proteoglycan receptors on cell surfaces and in the extracellular matrix (Reape and 
Groot 1999). This interaction has been demonstrated to be responsible for forming 
chemokine gradients over the endothelium which are critically involved in mediating 
the initial steps in leukocyte recruitment and subsequent transmigration. 
 
1.6 The cytoskeleton 
 
The eukaryotic cell can change its shape and in consequence it has the ability to move, 
secrete, and phagocytose. This feature of the eukaryotic cell is due to its cytoskeleton. 
As a very dynamical structure the cytoskeleton consists of a variety of protein 
filaments which are coupled to the cell membrane and the cytoplasm. By controlling 
cell shape, mobility, and contractility the cytoskeleton has been identified to play a 
crucial role in mediating the immune response. In the following chapter the three main 
components of the cytoskeleton and their regulation will be described.  
 
1.6.1 Cytoskeleton components  
 
The components of the endothelial cytoskeleton can be divided in three subclasses of 
protein filaments, whereby the different filaments consist of different protein subunits. 
The subclasses are intermediate filaments, microtubuli, and actin filaments which 
together form the dynamic framework of the cytoskeleton. 
 
1.6.1.1 Microtubuli  
 
Microtubuli filaments are the thickest of the mentioned filament subtypes. They have a 
diameter of 25 nm and consist of tubulin subunits. Tubulin is a cytoskeleton protein 
which can polymerize, resulting in a tube-like structure of filaments. Microtubuli are 
very prominent toward the center of the cell and much less so in the periphery 
(Connolly et al. 1981). Microtubuli are structure elements of the centrosomes and play 
a key role in giving strength to the cell, transport of cellular compounds and most 
notably in cell division. 
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1.6.1.2 Intermediate filaments 
 
The intermediate filaments represent the second subclass of protein filaments with a 
diameter of 10 nm. The diameter of the intermediate filaments ranks between the 
microtubuli and the actin filaments, and is therefore named intermediate. The 
intermediate filaments are responsible for the stabilisation and strength of the cell. 
They consist of long, cord like, fibrin protein subunits and can be divided into three 
classes according to their distribution: keratin filaments in epithelial cells, vimentin 
filaments in muscle and glia cells, and neuro filaments in neurones. Intermediate 
filaments are represented all over the cell, providing mechanical protection for the cell. 
 
1.6.1.3 Actin filaments 
 
Actin filaments are the thinnest of the three filament subclasses with a diameter of 
only 6 nm. This is why they are also named microfilaments. The structure of actin 
filaments is typically represented by a double-stranded helical polymere composed of 
several monomeric actin subunits (Meijerman et al. 1997). Actin filaments are present 
all over the cytoplasm of the cell, but they are found in highest concentrations directly 
under the cytoplasmic membrane. They are organized in bundles or nets. Actin 
filaments are the primary structures that mainly regulate the cell shape and motility by 
binding certain proteins. In regard of the pivotal role of the actin filaments in several 
inflammatory diseases such as atherosclerosis, the following section will give detailed 
information about regulation and function of this special cytoskeleton component.  
 
1.6.2 G-actin polymerization and stress fibers 
 
Endothelial cells contain the contractile protein actin in two different forms: in a 
filamentous form, called F-actin, and in a monomeric form, called G-actin (Tobacman 
and Korn 1983). Actin filaments are dynamical structures, and the shift between the 
monomeric and the polymeric form (figure 6) of this protein plays a central role in 
several cell functions, especially those involving cell shape and movement. With 
nearly 5%, actin is the most common protein in the eukaryotic cell (Carpenter 2000), 
whereby about half of the actin filaments are present in F-actin form and half in G-
actin form.  
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figure 6: schematic diagram of the actin polymerization 
 
G-actin polymerization requires the presence of ATP, K+ and Ca2+. The formation of 
F-actin filaments is limited by the rate of conversion of actin monomers into dimers 
and trimers (Carpenter 2000). Upon the time point of binding an actin trimer the 
polymerization is speeded up. Subsequently, the polymerization is regulated by the 
concentration of free G-actin monomers. In the next step actin binds ATP, and the 
monomer is incorporated into the polymer (figure 6). Short time after the association 
of the monomeric G-actin to the polymer F-actin strand, ATP is hydrolysed into ADP. 
This hydrolysis leads to the stabilization of the filament. Actin filaments contain two 
different ends, a faster growing plus end, also named barbed end, and a slower 
growing minus end, also named pointed end. 
The growth of F-actin filaments is determined by factors that regulate the breakdown 
of the filament by depolymerization. According to the polarity of F-actin filament 
ends, they are able to bind to several different modulating proteins. These actin 
binding proteins determine the superstructure of actin filaments. 
There is a variety of actin binding proteins, among which α-Actinin plays a crucial 
role in regulating the tertiary structure of F-actin filaments. α-Actinin is involved in 
the formation of actin bundles like those found in microvilli and especially in the so 
called stress fibers (Carpenter 2000). F-actin stress fibers additionally contain filamin, 
topomyosin and myosin in periodical order. Due to their association with myosin they 
provide contractile properties (Sanger et al. 1980). Formation of stress fibers leads to 
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increased adherence of the cell since stress fibers associate with the so called adhesive 
matrix contacts (focal adhesions) (Reinhard et al. 1995).  
F-actin stress fibers possess a dynamic, flexible structure which allows the cells to 
respond to stimuli such as TNF-α, by cell movement, cell division, and changes in cell 
shape.  
Another actin binding protein is Thymosin. It plays a key role in regulating actin 
polymerization by binding monomeric G-actin, and therefore creating a kind of deposit 
for further polymerization. Gelsolin functions by cleaving F-actin filaments and 
masking the capping end of the separated pieces. Gelsolin therefore mediates the 
disrupture of actin filaments and acts as a so called capping protein. On the other 
hand Profilin is an actin binding protein that is able to increase the polymerization rate 
by catalyzing the ADP/ATP exchange. A further actin binding protein that functions as 
a capping protein, is the small heat shock protein (HSP27). HSP27 has been shown 
to interact with the actin cytoskeleton.  
 
1.6.3 Heat shock protein 27 
 
The small heat shock protein HSP27 is a member of the multigene family of heat 
shock proteins comprising proteins with a molecular size between ten and 150 kDa. 
Heat shock proteins are found to be expressed in all major tissues (Benjamin and 
McMillan 1998). The name heat shock proteins derives from the early observation that 
heat stress (5°C over normal growth temperature) rapidly induces the expression of 
these proteins (Tissieres et al. 1974). Further research showed that HSPs could also be 
induced by various other stress factors than heat, including e.g. heavy metals, amino 
acid analogues, inflammation, and oxidative/ischemic stress. Consequently, the term 
heat shock family of stress proteins is preferred to characterize this protein family. 
Heat shock proteins mainly function as so called molecular chaperones by 
facilitating the refolding of partially denatured proteins into active conformations. 
Therefore, they play a crucial role in protein biosynthesis (Georgopoulos and Welch 
1993). 
After its discovery as an inhibitor of actin polymerization (Miron et al. 1991), HSP27 
was found to regulate the dynamic actin network of cells in many tissues. Diverse 
physiological stimuli, such as oxidative stress, cytokines, and growth factors 
dramatically increase the phosphorylation of HSP27. The Ser 15, Ser 78, and Ser 83 
residues have been shown to be involved in this stress-induced phosphorylation 
(Gaestel et al. 1991; Landry et al. 1992). The phosphorylation of HSP27 is catalyzed 
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by a member of the family of mitogen activated protein kinases (MAPK), the p38 
MAPK (Kyriakis and Avruch 1996). 
It has been demonstrated in diverse tissues that in response to stress factors, such as 
mentioned above, the p38 MAPK is rapidly stimulated, resulting in an increased 
activity of the mitogen activated kinase activated protein kinase-2 (MAPKAPK-2) and 
subsequently in the phosphorylation of HSP27 (Gaestel et al. 1991; Landry et al. 
1992). HSP27 therefore represents a downstream target of the p38 mitogen activated 
protein kinase (MAPK) (for review see (Obata et al. 2000)). As mentioned under 1.5.2, 
the function of HSP27 in regulating the actin cytoskeleton depends on the 
phosphorylation state and the secondary structure (formation of monomers or 
oligomers) of this protein (Lavoie et al. 1993). Unphosphorylated HSP27 inhibits the 
actin polymerization by depolarization of the actin filaments. This depolarization is 
mediated by the binding of monomers or small oligomers of HSP27 to the barbed end 
of the filament (Benndorf et al. 1994). In consequence, G-actin monomers are no 
longer able to be incorporated into the filament and the F-actin polymerization is 
inhibited. After phosphorylation by the mentioned MAPKAPK-2, HSP27 dissociates 
from the filament and the polymerization can continue (Benndorf et al. 1994). Besides 
this inhibitory property of HSP27 on the actin polymerization process, Miron and 
coworkers were able to show that HSP27 modulates existing actin filament structures 
by depolymerization (Miron et al. 1991). 
From the described actin binding proteins, especially heat shock protein HSP27 has 
been closely associated with the regulation of the tertiary structures of actin filaments 
such as stress fibers (Landry and Huot 1995).  
 
1.6.4 p38 mitogen activated protein kinase 
 
As described above, the activation of the p38 MAPK cascade is involved in activating 
HSP27 via phosphorylation of the mitogen activated kinase activated protein kinase-2 
(MAPKAPK-2) (Gaestel et al. 1991; Landry et al. 1992).  
Besides its role in activating HSP27 the p38 MAPK is involved in multiple other 
cellular responses which include the mitogen activated protein kinases (MAPK) 
signaling pathway. For example this pathway plays a key role in the recruitment of 
leukocytes to sites of inflammation and the release of certain chemokines, such as 
monocyte chemoattractant protein-1 (MCP-1) (see chapter 1.5). 
Therefore, the following chapter will give a short resume of the MAPK cascade with 
concentration on the p38 MAPK since this MAPK was investigated in the present 
work. 
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Via the MAPK signaling pathway the cell is able to transduce extracellular signals to 
intracellular response. To date, more than twelve MAPK have been identified and 
cloned. These twelve kinases can be divided into three subclasses, the stress-activated 
protein kinases/c-Jun N-terminal kinases (JNK/SAPK), the extracellular responsive 
kinases or extracellular regulated protein kinases (ERK), and the p38 MAPK 
(figure 7). The group of the p38 MAPK can be divided in several isoforms, which are 
classified due to their ability to respond to different stimuli. In endothelial cells mainly 
p38α, β, and γ are expressed, whereby p38δ is not found in these cells (Hale et al. 
1999).  
 
 
 
figure 7: schematic diagram of the MAPK cascade 
 
A common feature of all known MAPK is the phosphorylation at both threonine and 
tyrosine residues by a dual specific upstream MAPK kinase (MKK). The MKK itself 
is phosphorylated by an upstream MKK-kinase, also called MKKK (Herlaar and 
Brown 1999). Once activated, the different MAPK can phosphorylate and therefore 
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activate several more kinases. In a final step, the activated MAPK, like p38, is able to 
acivate proteins, such as transcription factors or as described here, HSP27. The p38 
MAPK is mainly activated by extracellular stress factors, like UV-light, osmotic shock 
(Herlaar and Brown 1999), and cytokines such as TNF-α. The p38 MAPK is activated 
by the upstream kinases MKK3 or 6, which are themselves a downstream targets of 
Rac and Cdc42 (Yuasa et al. 1998) (figure 7). Upon activation, p38 leads to 
phosphorylation of MAPKAP-2 followed by activation of HSP27. Therefore, p38 
MAPK is critically involved in the regulation and modulation of the actin 
cytoskeleton. 
 
1.6.5 MAPK phosphatase-1 
 
Besides the regulation of p38 phosphorylation by its upstream kinases MKK3 and 6, 
(see chapter 1.6.4), MAPK in mammalian cells are regulated by a family of dual-
specific MAPK phosphatases (MKP), which target the two critical phosphorylation 
sites (tyrosine and threonine) of MAPK. The first member of this expanding group of 
dual-specific phosphatases was isolated from the vaccinia virus in 1992 (Guan et al. 
1992), called VH1. Soon a mammalian homologue was isolated and cloned, termed 
VHR (Ishibashi et al. 1992). The 20 kDa VHR was followed by a number of further 
proteins, which were termed MKP (MAP kinases phosphatases), existing as MKP-1-5, 
MKP-X, B23, Pac-1, and M3/6 (Saxena and Mustelin 2000). These nine members of 
the MKP family share a common structure, comprising a catalytic domain with amino 
acid homology to VH1, and an amino-terminal noncatalytic domain with two short 
regions of sequence homology to the cdc25 phosphatase (Keyse and Ginsburg 1993; 
Keyse 1995). The MKP have been shown to provide a high specificity in 
dephosphorylating and therefore deactivating the main subtypes of the MAPK family 
(Alessi et al. 1993; Sun et al. 1993; Ward et al. 1994). MKP differ in their expression 
pattern in various cell types. Moreover, the expression of MKP upon various stimuli, 
such as heat shock, stress stimuli, and oxidative stress follow different kinetics 
(Saxena and Mustelin 2000). MKP-1/2, Pac-1, and B23 are predominantly expressed 
in the nucleus, and are induced by either growth factor or stress (Keyse 2000). M3/6, 
MKP-3/4/5, and MKP-X however are predominatly localized in the cytosol of 
mammalian cells (Keyse 2000). From the known MKP, MKP-1 (CL100) has been 
shown to be specifically responsible for the dephosphorylation of p38 (Chen et al. 
2001), which could neither be shown for MKP-2 (Chu et al. 1996) nor MKP-3 
(Nichols et al. 2000).  
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1.6.6 Endothelial permeability 
 
Due to the pivotal function of the endothelium to create a semi-permeable barrier 
between the blood and the interstitial space of all organs, and the fact that it is 
characterized by a large surface area, the endothelium represents a target for many 
inflammatory stimuli released during several inflammatory diseases (Brett et al. 1989; 
van Hinsbergh 1997; Wojciak-Stothard et al. 1998). 
Inflammatory stimuli, such as TNF-α, thrombin, or histamin are able to increase the 
endothelial permeability by formation of intercellular gaps in the vascular 
endothelium. The resulting increased vascular permeability is commonly attributed to 
the reorganization of F-actin filaments into stress fibers, followed by contraction of 
cells (Lum and Malik 1996), increased macromolecule permeability, and edema 
formation in the inflamed tissue.  
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2.1 Materials 
 
Rat ANP 99-126 (ANP) and CNP were purchased from Calbiochem (Schwalbach, 
Germany), 8-Br-cGMP was from Sigma (Taufkirchen, Germany). cANF was 
purchased from Saxon Biochemicals (Hannover, Germany). HS-142-1 was a gift from 
Dr. Matsuda, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., LTD, 
Shizuoka, Japan. Antiserum against the von Willebrand-factor was from Serotec 
LTD (Wiesbaden, Germany). GSNO (S-Nitroso-L-glutathione) and L-NNA (NG-
Nitro-L arginine) were from Alexis Biochemicals (Grünberg, Germany). Cell culture 
medium (M199) and penicillin/ streptomycine were from PAN (Aidenbach, Germany). 
Fetal calf serum was from Biochrom (Berlin, Germany), Endothelial Cell Growth 
Medium (ECGM®) from Promocell (Heidelberg, Germany). The enhanced 
chemoluminescence protein detection kit was purchased from NEN (Cologne, 
Germany); Complete® was obtained from Roche (Mannheim, Germany). anti-p50, 
anti-p65 (antibodies for Western blot and TransCruz® antibodies for supershift assays), 
anti-IκB-α, -β, and -ε antibodies, anti-MKP-1 and anti-HSP27 antibodies were 
purchased from Santa Cruz (Heidelberg, Germany), anti-phospho-IκB antibody, anti-
phospho-p38, anti-phospho-HSP27, and anti-phospho MKK3/6 polyclonal rabbit anti-
human antibodies were from Cell Signaling (Frankfurt/M, Germany), anti-p65 from 
Stressgen (San Diego, USA), peroxidase-conjugated goat anti-rabbit and donkey anti-
goat antibodies were from Jackson Immunolab (Dianova, Hamburg, Germany), and 
anti-p38 antibody from Calbiochem (Schwalbach, Germany). Rhodamin-conjugated 
phalloidin was from Molecular probes-Mobitec (Göttingen, Germay).  FITC-labeled 
antibodies against ICAM-1, VCAM-1, and E-selectin were from Biosource (Nivelles, 
Belgium), and FITC-labeled anti-rabbit antibody was from Dianova (Hamburg, 
Germany). The primer for RT-PCR for E-selectin, ICAM-1, and VCAM-1 were from 
Biosource Nivelles, Belgium), primer for MKP-1, MCP-1, IκB-α, GAPDH, decoy and 
scrambled oligonucleotides were from MWG-biotech AG (Ebersberg, Germany). All 
other materials were purchased from Sigma (Taufkirchen, Germany) or Merck-
Eurolab (Munich, Germany). 
 
Note: The experiments were performed with rat ANP 99-126, not human ANP, 
because first observations concerning ANP effects on TNF-α-induced cell changes 
were made after treatment with rat ANP. Moreover, as mentioned in the introduction, 
human ANP and rat ANP differ only in one amino acid. In case of human ANP it is 
methionine and in case of rat ANP it is isoleucine.  
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2.2 Cell culture 
 
Solutions: 
 
PBS:      PBS + : 
Na2HPO4 1.48 g (8.0 mmol/L) NaCl   8.00 g 
KH2PO4 0.43 g (1.5 mmol/L) KCl   0.20 g 
NaCl  7.20 g (160 mmol/L) Na2HPO4  1.15 g   
H2O       ad 1000 ml   KH2PO4  0.20 g 
      MgCl2 x 6 H2O 0.10 g 
      CaCl2   0.10 g  
      H2O           ad 1000 ml 
 
Trypsin/EDTA:  
Trypsin (diluted 1:250 in PBS)  0.05 g 
EDTA (Sigma)    0.20 g 
PBS                 ad 100 ml 
 
2.2.1 Cell isolation 
 
Human umbilical vein endothelial cells (HUVEC) were prepared by digestion of 
umbilical veins with 0.1 g/L of collagenase A (Roche, Mannheim, Germany) and were 
either grown in endothelial cell growth medium (ECGM, Promocell, Heidelberg, 
Germany) or in M199 (PAN, Aidenbach, Germany) supplemented with 20% heat-
inactivated FCS, 1x endothelial cell growth supplement (Sigma, Taufkirchen, 
Germany), and penicillin (100 U/ml)/streptomycine (100 ng/ml). In order to 
compensate inter-individual differences, cells of at least two umbilical cords were 
combined for each cell preparation.  
 
2.2.2 Passaging of HUVEC 
 
For passaging of HUVEC medium was removed and the cells were washed three times 
with ice-cold PBS+. Afterwards HUVEC where incubated with 2 ml trypsin/EDTA 
solution for 2 min at 37°C. The cells where gradually detached and the digestion of 
trypsin was stopped with M199 containing 10% FCS. After centrifugation at 218 x g, 
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4°C for 10 min the supernatant was discarded and the pellet was resuspended in M199 
supplemented with 20% heat-inactivated FCS, 1x endothelial cell growth supplement 
(Sigma, Taufkirchen, Germany), and penicillin (100 U/ml)/streptomycine (100 ng/ml). 
HUVEC were subcultured 1:3 in culture flasks or plates and grown until confluence. 
Experiments were performed with cells of passage number three or four grown until 
confluence in 6-, 12-, or 24-well plates (Peske, Aindling-Pichl, Germany). HUVEC 
were found > 95% pure as judged by FACS analysis (FACScan, Becton Dickenson, 
Heidelberg, Germany), using an antiserum against the von Willebrand-factor 
(Serotec LTD, Wiesbaden, Germany). 
 
2.2.3 Freezing, storage, and thawing of HUVEC 
 
For long time storage confluent HUVEC monolayers were trypsinized and the 
detached cells were centrifuged at 218 x g for 10 min, 4°C. The pellet was 
resuspended in 1.5 ml freezing medium [M199 supplemented with 20% heat-
inactivated FCS, 1x endothelial cell growth supplement (Sigma, Taufkirchen, 
Germany)], containing 10% [v/v] DMSO. Cells in cryovials were gradually frozen at 
20°C for one day, overnight at -80°C and than stored at -196°C in liquid nitrogen. For 
thawing, cells were rapidly warmed at 37°C and for removing DMSO centrifuged at 
218 x g for 10 min, 4°C in M199 containing 10% FCS. The supernatant was discarded 
and the pellet was resuspended in culturing medium. Cells were subcultured into 
culture plates and cultivated until confluence. 
 
2.3 Flow cytometric analysis of cell adhesion molecules 
 
Solutions: 
 
FACS-buffer:  
NaCl  8.12 g 
KH2PO4 0.26 g 
Na2HPO4 2.35 g 
KCl  0.28 g 
Na2EDTA 0.36 g 
LiCl  0.43 g 
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Na-azide 0.20 g 
H2O        ad 1000 ml pH 7.37 
 
PBS/PBS+  
Trypsin/EDTA see under 2.2 
 
Used antibodies: 
 
Sheep anti-human von Willebrand Factor: FITC (Serotec) 
Mouse anti-human Vascular Cell Adhesion Molecule-1 (VCAM-1) 
(Biosource) 
Anti-ELAM-1, FITC/mouse anti human CD62 E (Calbiochem) 
Mouse anti-human Intercellular Adhesion Molecule-1/FITC (ICAM-1) 
(Biosource) 
 
Experimental procedure: 
 
HUVEC (24 well plates, 200 µl) were grown until confluence and were left either 
untreated or treated with TNF-α (10 ng/ml, Sigma, Taufkirchen, Germany). The effect 
of the following substances on the surface expression of cell adhesion molecules was 
determined: ANP (10-8-10-6 mol/L), CNP (10-8-10-6 mol/L), cANF (10-6 mol/L), 8-Br-
cGMP (10-3 and 10-4 mol/L), and HS-142-1 (10 µg/ml). Substances were added to the 
cells 30 min before TNF-α. After 5 h (E-selectin) or 6 h (ICAM-1, VCAM-1), surface 
expression of adhesion molecules was measured by flow cytometry using FITC-
labeled antibodies against ICAM-1, VCAM-1, and E-selectin (Biosource, Nivelles, 
Belgium). Briefly, cells were washed with ice-cold PBS three times and trypsinized. 
After scraping the cells with a rubber policeman and transferring them into FACS 
tubes the digestion was stopped by addition of M199 containing 10% FCS. After 
centrifugation (218 x g, 4°C, 15 min), the cell pellet was washed with ice-cold PBS 
three times. Cells were incubated with 1% bovine serum albumine (BSA) for 30 min at 
room temperature. After 30 min of incubation with the respective antibody the cells 
were again washed with PBS and resuspended in a volume of 300 µl PBS for flow 
cytometric analysis. For the adjustment of instrument settings control cells were 
prepared by performing the procedure as described above but by omitting the addition 
of the antibody. In each experiment the mean fluorescence of TNF-α treated cells was 
set as 100% and all other treatment conditions were compared to this group. At least 
three different sets of experiments with cells from different isolations were performed 
in triplicates. 
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2.4 Electrophoretic mobility shift assay 
 
2.4.1 Isolation of nuclear and cytosolic protein 
 
Solutions: 
 
Buffer A:      Buffer B: 
HEPES pH 7.9 (Sigma)  10 mmol/L       HEPES pH 7.9  20 mmol/L  
KCl (Merck)    10 mmol/L  NaCl (Roth)    0.4 mol/L 
EDTA (Sigma)  0.1 mmol/L  EDTA       1.0 mmol/L 
EGTA (Sigma)  0.1 mmol/L  EGTA         1.0 mmol/L 
H2O              ad 50 ml  Glycerol (100%)  25% 
     H2O               ad 50 ml 
 
DTT  1.0 mmol/L (fresh)  
PMSF  0.5 mmol/L (fresh) 
DTT stock solution: 1 ml of a 1 mol/L solution was aliquoted and stored at -20° C  
PMSF stock solution: 1 ml of a 50 nmol/L solution in isopropanol was aliquoted  
and stored at -20° C  
 
Experimental procedure: 
 
HUVEC were cultured in 6-well plates until confluence and were either left untreated 
or stimulated with TNF-α (10 ng/ml) for 1 h in the presence or absence of ANP (10-7-
10-6 mol/L), CNP (10-8-10-6 mol/L), or 8-Br-cGMP (10-3 mol/L), which were added to 
the cells 30 min before TNF-α. Nuclear and cytosolic extracts were prepared as 
described in (Schreiber et al. 1989). Briefly, HUVEC were washed with PBS, scraped, 
and resuspended in 400 µl of hypotonic buffer A. Cells were allowed to swell on ice 
for 15 min. Nonidet P-40 (10%, 25 µl) was added followed by 10 sec of vigorous 
vortexing and centrifugation at 12,000 x g for 30 sec. The supernatant (containing the 
cytosolic protein) was removed and frozen at -20 °C for Western blot analysis. The 
nuclear pellet was extracted with 50 µl of hypertonic buffer B by shaking at 4°C for 15 
min. The extract was centrifuged at 12,000 x g and the supernatant was frozen at 
-85°C. Protein concentrations were determined by the method of Lowry (Lowry OH 
1951). 
 
MATERIALS AND METHODS 
 42
2.4.2 Radioactive labeling of oligonucleotides  
 
Solutions: 
 
5 x binding buffer:    
Glycerol   20% (v/v) 
MgCl2    5.0 mmol/L 
EDTA   2.5 mmol/L 
NaCL    250.0 mmol/L 
Tris-HCl (Roth) pH 7,5 50 mmol/L 
H2O    ad 50 ml 
 
DTT: final concentration 2.5 mM added directly 
 
Loading buffer:   
Tris-HCl (Roth) pH 7,5 250 mmol/L 
Bromphenolblue (Sigma) 0.2% (m/v) 
Glycerol   40% (v/v) 
 
10 x TBE buffer:   
Tris-Base (Roth)  900 mmol/L 
Boric acid   25 mmol/L 
H2O    ad 1000 ml 
 
PAGE-non denaturing 4.5% Gel:   
10 x TBE    1 ml  
Acrylamide-bis 30 % (Roth) 3 ml 
Glycerol (100%)   500 µl 
H2O     15.5 ml 
TEMED (N,N,N´,N´-tetramethylethylendiamine) 10 µl 
APS (Ammonium persulfate) 10% (m/v)   150 µl     
 
Experimental procedure: 
 
A 22-mer double-stranded oligonucleotide probe containing a consensus binding-
sequence for NF-κB (5'-AGT TGA GGG GAC TTT CCC AGG C-3', Promega, 
Mannheim, Germany), AP-1 (5`-CGC TTG ATG AGT CAG CCG GAA-3`), AP-2 
(5`-GAT CGA ACT GAC CGC CCG CGG CCC GT-3`) or Sp-1 (5'-ATT CGA TCG 
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GGG CGG GGC GAG C-3', Promega, Mannheim, Germany) was 5' end-labeled with 
[γ 32P]-ATP (10 µCi) using T4 polynucleotide kinase.  
 
2.4.3 Binding reaction and electrophoretic separation 
 
Equal amounts of nuclear protein (10 - 20 µg) were incubated (20 min, RT) in a 15 µl 
reaction volume containing 10 mmol/L Tris-HCl pH 7.5, 5 x 104 cpm radiolabeled 
oligonucleotide probe, 2 µg poly (dIdC), 4% glycerol, 1 mmol/L MgCl2, 0.5 mmol/L 
EDTA, 50 mmol/L NaCl, and 0.5 mmol/L DTT. Nucleoprotein-oligonucleotide 
complexes were resolved by electrophoresis (4.5% non-denaturing polyacrylamide gel, 
100 V) and bands were visualized by phosphorimaging (Packard, Meriden, USA). 
Specificity of the DNA-protein complex was confirmed by competition with a 100-
fold excess of unlabeled NF-κB, SP-1, and AP-2 (5'-GAT CGA ACT GAC CGC CCG 
CGG CCC GT-3') binding sequences, respectively.  
 
2.4.4 Supershift assay 
 
Solutions (see 2.4.3 electrophoretic mobility shift assay) 
 
Used antibodies: 
 
Anti-p65 NF-κB (Santa Cruz, Heidelberg, Germany) 
Anti-p50 NF-κB (Santa Cruz) 
Anti-c-jun  (Santa Cruz) 
Anti-c-fos  (Santa Cruz) 
 
Experimental procedure: 
 
For supershift analysis, 1 µg of antibodies against p50 , p65, c-jun, or c-fos was added 
to the reaction mixtures 10 min before the addition of radiolabeled probe. 
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2.4.5 Decoy experiment 
 
For Decoy experiments HUVEC were transiently transfected with decoy (5`-CGC 
TGG ATG AGT CAG CCG GAA-3`) or scrambled (5`-CAG GAG AGT ATC CTG 
CGA TGC ATC TGC T-3`) oligonucleotides (0,04 µg/well) using an EffecteneTM 
transfection kit (Quiagen, Hilden Germany). After 4 hours and addition of fresh 
medium, cells were treated for EMSA. 
 
2.5 Western blot analysis 
 
Solutions: 
 
RIPA buffer (lysis buffer): 
NaCl   150 mmol/L 
Tris-HCl  50 mmol/L 
Nonidet P40  1.00% (v/v) 
Deoxycholat   0.25% (v/v) 
SDS    0.10% (m/v) 
H2O   ad 1000 ml  
+  DTT final concentration 1 mmol/L added freshly before use 
+  PMSF final concentration 1 mmol/L added freshly before use 
+  Complete(Protease inhibitor) 25x stock solution  
added freshly before use  
 
for detection of phospho-MAPK:  
NaF  final concentration 50 mmol/L and 
Na3VO4 final concentration 50 mmol/L were added in order to inhibit 
phosphatases 
 
SDS Sample buffer (5 x) was stored at -20°C and added freshly before use 
Tris-HCl (pH 6.8)  3.125 mol/L 
Glycerol   5% (v/v) 
SDS (ICN biomedicals) 20% (m/v) 
DTT    16% (m/v) 
Pyronin Y (Sigma)  5% (m/v) 
H2O    ad 1000 µl 
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Resolving gel 10% :  
Acrylamide 30%-Bisacrylamide 0.8% solution (Roth)   5.0 ml  
Tris-base pH 8.8 (Roth) final concentration    1.5 mol/L 
10% SDS         0.15 ml 
H2O          ad 6.10 ml 
The solution was degassed 10 min before addition of: 
15 µl TEMED (cross linker) and 
75 µl APS (radical starter)  
to ensure anaerobic conditions. 
 
Stacking gel 10%: 
Acrylamide 30%-Bisacrylamide 0.8% solution (Roth)  1.70 ml             
Tris-base pH 6.8 (Roth) final concentration   1.25 mol/L 
10% SDS        0.10 ml 
H2O         7.00 ml 
The solution was degassed 10 min before addition of: 
+ 20 µl TEMED (cross linker) 
+ 100 µl APS (radical starter) 
 
Electrophoresis buffer:  
Tris-base  3 g 
Glycin 14.4 g 
SDS  1.0 g 
H2O  ad 1000 ml 
 
Anode buffer I pH 10.4: 
Tris-base 15 g 
+ 100 ml Methanol 
+ 400 ml H2O dest. 
 
Anode buffer II pH 10.4: 
Tris-base 1.5 g 
+ 100 ml Methanol 
+ 400 ml H2O dest. 
 
Cathode buffer pH 7.6: 
ε-Amino-n-caproic acid 2.6 g 
+ 100 ml Methanol 
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+ 400 ml H2O dest. 
 
Tris buffered saline solution containing Tween pH 8.0 (TBS-T): 
Tris-base     3.0 g 
NaCl     11.1 g  
Tween 20     1 ml 
H2O     ad 1000 ml 
Primary antibodies: 
Phospho-HSP27 (Ser 32) Antibody  Cell signaling  
Phospho-p38 MAP Kinase Antibody Cell signaling    
Anti-p38/HOG1    Calbiochem      
MKP-1 (V-15) sc1199 Antibody  Santa Cruz      
Phospho-IκB (Ser 32) Antibody  Cell signaling    
I-κB -α, -β, -ε, Antibody   Santa Cruz      
NF-κB p65 (C-20)-G  sc-372-G (goat) Santa Cruz      
NF-κB p50 (C-20)-G  sc-1192-G (goat) Santa Cruz      
anti-Sp1      Santa Cruz       
anti-actin      Chemicon international 
anti-α-tubulin     Sigma       
 
Secondary antibodies: 
Peroxidase-conjugated donkey anti goat IgG     Jackson I. research 
Peroxidase-conjugated goat anti rabbit IgG       Jackson I. research 
 
Experimental procedure: 
 
For detecting proteins in whole cell lysates HUVEC were cultured in 12-well plates 
until confluence and were either left untreated or stimulated with TNF-α (10 ng/ml) in 
the presence or absence of ANP (10-6 mol/L), which was added to the cells 30 min 
before TNF-α incubation. Briefly, cells were washed with ice-cold PBS and lysed in 
RIPA buffer which was supplemented with a protease inhibitor cocktail (Complete®), 
1 mmol/L DTT, and 1 mmol/L PMSF. For determination of phospho-IκB, 
phospho-HSP27, and phospho-p38, 50 mmol/L NaF and 50 mmol/L sodium vanadate 
were additionally added. In some cases Western blots were performed after pretreating 
the cells with actinomycin D (2 µmol/L for 30 min). For investigating proteins in 
cytosolic or nuclear fractions, the isolation of cell fractions was performed as 
described under 2.4.1. Cells were homogenized and centrifuged at 12,000 x g for 
10 min at 4°C. After determination of protein concentrations in the supernatant by the 
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method of Lowry (Lowry OH 1951), sample buffer was added to the probes. The 
samples were heated at 95°C and loaded onto an SDS/PAGE gel (10%) for protein 
separation, electroblotted, and the respective proteins were detected using the 
mentioned antibodies. An enhanced chemoluminescence protein detection kit (NEN, 
Cologne, Germany) and a Kodak Image station (Kodak digital science, Stuttgart, 
Germany) were used for visualization of the bands. 
 
2.6 Enzyme-linked immunosorbent assay (ELISA) 
 
For ELISA HUVEC were grown until confluence in 24-well plates. Cells were left 
either untreated or treated with TNF-α (10 ng/ml). The effect of the following 
substances on the expression of TNF-α-induced MCP-1 was determined: ANP (10-11-
10-6 mol/L), cANF (10-8-10-6 mol/L), 8-Br-cGMP (10-10-10-3 mol/L), CNP (10-11-10-6 
mol/L), GSNO (S-Nitroso-L-glutathione 125 and 500 µmol/L) and L-NNA (NG-Nitro-
L arginine, 125 and 500 µmol/L). Substances were added to the cells 30 min before 
TNF-α. After 6 h the supernatants (200 µl) were transferred into a 96-well microtiter 
plate and the measurement of surface expression of human MCP-1 was determined by 
an ELISA based on commercial antibody pairs (R&D, Wiesbaden, Germany). Binding 
of biotinylated antibody was quantified using streptavidin-peroxidase (Jackson 
Immuno Research, West Grove, PA, USA) and the substrate TMB (3,3',5,5'-
tetramethylbenzidine, Sigma). Recombinant MCP-1 (R&D) served as standard. 
2.7 Antisense assay 
 
Experimental procedure: 
 
For antisense experiments, HUVEC were cultured in 12-well plates until confluence. 
Phosphorothioate oligonucleotides (modifications are shown by small letters in the 
oligonucleotide sequence) were used in a final concentration of 0.03 µg/well for each 
transfection reaction. The used oligonucleotides for MKP-1 were: antisense, 5`-cc-
CACTTCCATGACCA-tgg-3´; sense, 5`-cc-ATGGTCATGGAAGT-ggg-3`. The cells 
were transfected using an EffecteneTM transfection kit (Qiagen, Hilden, Germany). The 
mentioned amount of antisense or sense DNA was diluted in water and after addition 
of an appropriate amount of Enhancer, Effectene reagent was added and the mixture 
was incubated for 10 min at RT to allow Effectene-reagent-DNA complex formation. 
During this incubation time HUVEC medium was removed from the monolayers and 
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fresh M199, supplemented with 20% heat-inactivated FCS, 1x endothelial cell growth 
supplement, and penicillin (100 U/ml)/streptomycine (100 ng/ml), was added. The 
transfection complex was added to the cells for an incubation of 3 h. Subsequently 
medium containing transfection complex was removed and fresh medium was added. 
Cells were either left untreated or stimulated with TNF-α (10 ng/ml) in the presence or 
absence of ANP (10-6 mol/L), which was added to the cells 30 min before TNF-α 
incubation. The stimulation time was 30 and 60 min for MKP-1, 15 min for phospho-
p38 detection by Western blot, and 6 h for detection of human MCP-1 protein by 
ELISA. Western blot and ELISA were performed as described under 2.6.  
2.8 Detection of mRNA 
 
Used primer: 
 
 sense primer antisense primer 
ICAM-1 5`-TAT-GGC-AAC-GAC-TCC-TTC-T-3` 5`-CAT-TCA-GCG-TCA-CCT-TGG-3` 
VCAM-1   5`-ATG-ACA-TGC-TTG-AGC-CAG-G-3` 5`-GTG-TCT-CCT-TCT-TTG-ACA-CT-3` 
E-Selectin 5`-CTC-TGA-CAG-AAG-AAG-CCA-A-3` 5`-ACT-TGA-GTC-CAG-TGA-AGC-CA-3` 
IκB-α 5`-CGG-AAT-TCC-AGG-CGG-CCG-AGC-
GCC-CC-3´ 
5`-GGG-GTA-CCT-CAT-AAC-GTC-AGA-
CGC-TG-3` 
MKP-1 5`-GCT-GTG-CAG-CAA-CAG-TC-3` 5`-TAC-CTT-ATG-AGG-ACT-AAT-CG-3` 
MCP-1 5`-GAT-GCA-ATC-AAT-GCC-CCA-GT-3` 5`-TTG-CTT-GTC-CAG-GTG-GTC-CAT-3` 
GAPDH 5`-TCA-CTC-AAG-ATT-GTC-AGC-AA-3` 5`-AGA-TCC-ACG-ACG-GAC-ACA-TT-3` 
 
Conditions: 
 
 denaturing  annealing  extension cycles 
ICAM-1 94°C for 1 min 55°C for 1 min 72°C for 1 min 30 
VCAM-1   94°C for 1 min 55°C for 1 min 72°C for 1 min 30 
E-Selectin 94°C for 1 min 55°C for 1 min 72°C for 1 min 30 
IκB-α 94°C for 1 min 55°C for 2 min 72°C for 2 min 35 
MKP-1 95°C for 1 min 57°C for 2 min 72°C for 1 min 35 
MCP-1 94°C for 50 sec 55°C for 1 min 72°C for 1 min 28 
GAPDH 93°C for 24 sec 55°C for 30 sec 73°C for 1 min 30 
 
HUVEC were treated with ANP (10-8-10-6 mol/L) or TNF-α (10 ng/ml) alone or in 
combination for 10 min up to 8 h. RNA was prepared using RNeasy® RNA isolation 
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kit (Qiagen, Hilden, Germany). Reverse transcription was performed using a reverse 
transcription system kit (Promega, Mannheim, Germany). RT-PCR experiments were 
performed with primers for ICAM-1, VCAM-1, E-Selectin, IκB-α, MKP-1, iNOS, 
MCP-1, and GAPDH (see above). PCR was followed by gel electrophoresis, ethidium 
bromide staining, and densitometric analysis (Kodak Image station, Kodak digital 
science, Stuttgart, Germany).  
 
2.9 Microscopic investigations 
 
Solutions: 
 
3.7% (v/v) paraformaldehyde (Sigma) 
PBS+ see 2.2 Cell Culture 
Triton X-100 0.1% (v/v) (Sigma) 
BSA-bovine serum albumin (Sigma) 1% in PBS  
 
2.9.1 Immunocytochemistry 
 
Used antibodies: 
 
Anti-ELAM-1, FITC/mouse anti-human CD62 E (Calbiochem)  
Mouse anti-human Intercellular Adhesion Molecule-1/FITC (Biosource) 
Rabbit polyclonal anti-p65 antibody (Stressgen, San Diego, USA) 
 
Experimental procedure: 
 
HUVEC were cultured in 24-well plates until confluence and either left untreated or 
stimulated with TNF-α (10 ng/ml) for 1 h (p65), 5 h (E-selectin), or 6 h (ICAM-1) in 
the presence or absence of ANP (10-6 mol/L, which was added to the cells 30 min 
before TNF-α). Cells were washed with PBS+ three times and fixed with 3.7% 
paraformaldehyde for 10 min at RT (20°C).  
After fixation the cells were washed, incubated with a 1% solution of BSA (30 min, 
RT), followed by antibody binding for 30 min at 4°C in the darkness. Visualization of 
adhesion molecules was performed with a Zeiss Axiovert 25 microscope (Zeiss, 
Munich, Germany, 400-fold magnification, 450 nm emission wavelength).  
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For p65 staining the cells were washed twice with PBS+ after fixation and 
permeabilized for 10 min with 0.2% Triton X-100. The cells were washed again and 
incubated with a 1% solution of BSA (30 min, RT), followed by staining with an anti-
p65 antibody for 1 h at 4°C and a secondary FITC-labeled anti-rabbit antibody. After 
washing the cells p65, ICAM-1, and E-Selectin were visualized in a Zeiss Axiovert 25 
microscope (Zeiss, Munich, Germany) at 450 nm emission wavelength with a 400-fold 
magnification.  
 
2.9.2 Morphological investigations 
 
HUVEC (24-well plates) were either left untreated or stimulated with TNF-α (10 
ng/ml) in the presence or absence of ANP (10-6 mol/L), which was added to the cells 
30 min before TNF-α. After 1 or 24 h cells were washed with PBS+ three times and 
stained with Haemacolor® (Merck, Munich, Germany) as indicated by the 
manufacturer. Cells were photographed with a Zeiss Axioskop MC 80 DX microscope 
(Zeiss, Munich, Germany) with a 200- or 400-fold magnification. 
 
2.9.3 Actin staining 
 
HUVEC (24-well plates) were either left untreated or stimulated with TNF-α (10 
ng/ml) for 30 min in the presence or absence of ANP (10-6 mol/L) or the p38 MAPK 
inhibitor SB203580 (5 or 10 µmol/L, Calbiochem, Schwalbach, Germany). ANP and 
SB203580 were added to the cells 30 min before TNF-α. Cells were washed with 
PBS+ three times and fixed with 3.7% paraformaldehyde for 10 min (RT). After 
washing twice, cells were permeabilized for 5 min with 0.1% Triton X-100 (RT) and 
washed again. Cells were incubated with a 1% solution of BSA (30 min, RT), and 
stained with rhodamine-phalloidine (0.16 mol/L) for 20 min at 4°C in the darkness. 
After washing, stained F-actin was visualized using a Zeiss Axiovert 25 microscope 
(Zeiss, Munich, Germany) with a 200- or 400-fold magnification (excitation: 554 nm; 
emission: 573 nm). 
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2.10 Quantification of F-actin 
 
Solutions: 
 
3.7 % (v/v) paraformaldehyde  
PBS+ see 2.2 Cell culture 
Triton X-100 0.1% (Sigma) 
BSA bovine serum albumin 1% in PBS  
Experimental procedure: 
 
HUVEC were cultured in 24-well plates and were left either untreated or treated with 
TNF-α (10 ng/ml). The effect of ANP (10-10-10-6 mol/L), SB203580 (10-5 mol/L), and 
8-Br-cGMP (10-3 and 10-4 mol/L) alone or in combination with TNF-α on F-actin 
formation was determined. Substances were added to the cells 30 min before TNF-α. 
F-actin staining was performed as described above. Bound dye was extracted from the 
cells with 1.5 ml of methanol (1 h, 4°C, in the dark). Fluorescence of the methanolic 
dye solution was measured in a Shimadzu spectrofluorophotometer RF 1501 
(Shimadzu Duisburg, Germany) (excitation: 554 nm; emission: 573 nm). The mean 
fluorescence of TNF-α-treated cells was set as 100% and all other treatment 
conditions were compared to this group. 
 
2.11 Permeability assay 
 
HUVEC were cultured in 12-well transwell clear plates (0.4 µm pore size, Costar 
Cambridge) in a volume of 500 µl (upper compartment). Cells were either left 
untreated or stimulated with TNF-α (25 ng/ml) with or without ANP (10-6 mol/L) or 
SB203580 (1 µg/ml), added to the cells 30 min before TNF-α. After 24 h, 100 µl of 
fluoresceine-isothiocyanate-labeled BSA (FITC-BSA, 10 mg/ml, Sigma, Taufkirchen, 
Germany) was given to the cells. Cell culture medium from the lower compartment 
(1,500 µl) was removed after 60 min. FITC-BSA was quantified in a Shimadzu 
spectrofluorophotometer RF 1501 (Shimadzu Duisburg, Germany) at a wavelength of 
538 nm (excitation 485 nm). BSA flux is expressed as ratio between fluorescence 
intensities in the lower compartment (after 60 min) and the upper compartment (0 
min). 
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2.12 MTT cytotoxicity assay  
 
Solutions:  
 
5 mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenylthetrazolium bromide] 
(Sigma, Taufkirchen, Germany) in PBS, sterile. 
Experimental Procedure: 
 
For MTT assay HUVEC were seeded into 96-well plates and cultured until 
confluence. The culturing medium was discarded and cells were incubated for at least 
6 h with all substances, in the highest concentrations used, in 50 µl M199 containing 
10% FCS. Afterwards 5 µl MTT reagent was added for an overnight incubation at 
37°C. The next day 250 µl DMSO was added to the supernantant for 3 h. Absorbtion 
was measured in an SLT Spectra ELISA reader (SLT Labinstruments, Crailsheim, 
Germany) at 570 nm. 
The results of the MTT cytotoxicity assay demonstrated that none of the used 
substances had any cytotoxic effect on HUVEC (data not shown). 
 
2.13 Statistical analysis 
 
All experiments were done from cells of at least three different cell preparations. Each 
experiment was performed at least in triplicates. Data are expressed as mean ± S.E.M. 
Values with p≤0.05 were considered statistically different compared to 100% or 1-fold 
(TNF-α treated cells) (one sample t-test). Statistical analysis was performed with 
Graph Pad Prism (version 3.02). 
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3.1 Adhesion molecules 
3.1.1 ANP inhibits TNF-α-induced expression of adhesion 
molecules  
 
In order to determine the influence of ANP on the TNF-α-induced expression of the 
three adhesion molecules ICAM-1, VCAM-1, and E-selectin, the mRNA expression 
and cell surface protein levels were determined by RT-PCR, flow cytometry and 
immunocytochemistry. 
 
3.1.1.1 mRNA expression of adhesion molecules 
 
TNF-α treatment (10 ng/ml) of cells significantly induced CAM mRNA in HUVEC 
(figure 8). ANP dose-dependently (10-8-10-6 mol/L) reduced the TNF-α-induced 
mRNA expression of E-selectin and ICAM-1, whereas it did not affect VCAM-1 gene 
expression (figure 8).  
 
figure 8: Dose-dependent inhibition of E-selectin and ICAM mRNA expression by ANP. 
HUVEC were cultured in either medium alone (Co), or in medium containing TNF-α (10 ng/ml) with 
or without pretreatment (30 min) of the cells with various concentrations of ANP (10-8-10-6 mol/L). 
RT-PCR was performed as described under Materials and methods. Data show representative gels 
out of three independent experiments performed, each. Histograms show densitometric evaluation of 
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signal intensities normalized on GAPDH and are expressed as percentage of values for TNF-α 
treatment only. Data show mean ± S.E.M. of three independent experiments from different cell 
preparations. *** p<0.001 and ** p<0.01 represent significant differences compared to the values seen 
in TNF-α-activated cells. 
 
3.1.1.2 Expression of surface protein 
 
After showing the inhibitory action of ANP on the TNF-α-induced mRNA expression 
of ICAM-1 and E-selectin but not VCAM-1, the expression of surface protein of the 
three adhesion molecules was investigated by flow cytometry (figure 9) and 
immunocytochemistry (figure 10). 
 
ANP pretreatment dose-dependently reduced E-selectin and ICAM-1 surface protein, 
but did not affect levels of VCAM-1 (figure 9). Interestingly, ANP (10-6 mol/L) alone 
slightly but significantly elevated basal ICAM-1 expression. 
 
figure 9: Flow cytometry analysis of ICAM-1, VCAM-1 and E-selectin surface protein 
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E-selectin, ICAM-1, and VCAM-1 expression was detected by the corresponding FITC-labeled 
antibodies in untreated, TNF-α-treated, and TNF-α + ANP (10-8-10-6 mol/L) treated cells, whereby 
ANP was added 30 min before TNF-α. Data in the left panels show representative histogram out of 6 
independent experiments. Demonstrating numbers of cells vs. fluorescence intensity at 520 nm. Data 
in the right panel show mean fluorescence ± S.E.M. of three independent experiments from different 
cell preparations. *** p<0.001 and ** p<0.01 represent significant differences compared to the values 
seen in TNF-α-activated cells, whereby TNF-α was set as 100%. ++ p<0.01 represents significant 
differences compared to the values seen in control cells.  
 
The results of immunofluorescence staining for E-selectin and ICAM-1 are shown in 
figure 10. Increased staining of E-selectin and ICAM-1 was seen in TNF-α-treated 
cells, which was reduced in cells pretreated with ANP (10-6 mol/L). 
 
 
 
figure 10: Immunofluorescence staining of ICAM-1 and E-selectin surface protein 
After treatment with TNF-α in the presence or absence of ANP (10-6 mol/L, 30 min pretreatment), 
monolayers were washed and stained for CAM as described under Materials and methods. The 
pictures show a representative photograph out of three independent experiments (original 
magnification 400-fold). 
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3.1.2 Receptor specificity of the ANP effect on CAM  
 
For clarifying the receptor specificity of the inhibitory effect of ANP on CAM 
expression, the following substances were tested for their influence on the TNF-α-
induced expression of adhesion molecules: the specific NPR-C ligand cANF, an 
antagonist of the guanylyl-cyclase-coupled NPR-A, HS-142-1 (Morishita et al. 1991), 
and the cell-permeable analogue of cGMP, 8-Br-cGMP. Experiments with the 
mentioned substances were performed with TNF-α-treated cells by flow cytometry. 
 
The specific NPR-C ligand cANF did neither affect basal nor TNF-α-induced 
expression of CAM as shown in figure 11. 
 
 
figure 11: Effect of the NPR-C specific ligand cANF on CAM expression 
CAM expression of control cells (Co) or of cells treated with TNF-α (10 ng/ml), was determined by 
flow cytometry as described under Materials and methods. The effect of cANF (10-6 mol/L) on the 
expression of E-selectin and ICAM-1 was determined for cANF added to the cells 30 min before TNF-
α, or for cANF given to the cells alone for 6 hours. Data in the left panel show representative 
histogram out of 6 independent experiments. Demonstrating numbers of cells vs. fluorescence 
intensity at 520 nm. Data in the right panel show mean fluorescence ± S.E.M. of three independent 
experiments from different cell preparations, whereby TNF-α was set as 100%. 
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The antagonist of the guanylyl-cyclase-coupled NPR-A, HS-142-1, abrogated the 
effect of ANP on both TNF-α-induced expression of E-selectin as well as on ICAM-1, 
whereas HS-142-1 alone had no effect on basal CAM expression (figure 12). The cell-
permeable analogue of cGMP, 8-Br-cGMP, significantly reduced TNF-α-induced 
CAM expression in a dose-dependent manner (figure 12). 
 
figure 12: Effect of HS-142-1 and 8-Br-cGMP on TNF-α-induced CAM expression 
The A receptor antagonist HS-142-1 (HS 10 µg/ml) was given to the cells alone or in combination 
with TNF-α, in the presence or absence of ANP (10-6 mol/L). Furthermore, the effect of 8-Br-cGMP 
(10-3 - 10-4 mol/L) on TNF-α-induced CAM expression was determined by addition of 8-Br-cGMP 
30 min before TNF-α. Results are shown as histograms (dose 8-Br-cGMP 10-3 mol/L, left panel) 
showing numbers of cells vs. fluorescence intensity at 520 nm. Data in the right panel show mean ± 
S.E.M. of three independent experiments form different cell preparations. *** p<0.001 and ** p<0.01 
represent significant differences compared to the values seen in TNF-α-activated cells, whereby TNF-
α was set 100%. + p<0.01 represents significant differences compared to the values seen in TNF-α + 
ANP activated cells.  
 
These results suggest that the inhibition of CAM surface expression by ANP was 
mediated via the guanylyl-cyclase-coupled NPR-A, and therefore by cGMP as second 
messenger. 
 
After demonstrating, that the NPR-A receptor is involved in mediating the inhibitory 
action of ANP on TNF-α-induced expression of E-selectin and ICAM-1, it was 
investigated whether the other guanylyl-cyclase-coupled receptor, NPR-B, is also able 
to mediate this inhibitory property of ANP. Therefore the effect of the specific NPR-B 
ligand, CNP, on cell surface expression of CAM was tested. CNP also significantly 
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inhibited the TNF-α-induced expression of both E-selectin and ICAM-1 (figure 13). 
CNP alone did not affect basal CAM expression. 
 
figure 13: Effect of the NPR-B specific ligand CNP on CAM expression 
CNP (10-8-10-6 mol/L) was added to the cells in combination with TNF-α (30 min pretreatment) and 
flow cytometry was performed as described under Materials and methods. Data in the left panel 
show representative histograms (dose CNP 10-6 mol/L) demonstrating numbers of cells vs. 
fluorescence intensity at 520 nm. Data in the right panel show mean fluorescence ± S.E.M. of three 
independent experiments from different cell preparations. *** p<0.001 and ** p<0.01 represent 
significant differences compared to the values seen in TNF-α-activated cells, whereby TNF-α was set 
as 100%. 
 
Due to the fact, that the specific NPR-B receptor ligand, CNP, did also significantly 
reduce the surface expression of the two CAM, the other guanylyl-cyclase-coupled 
receptor, NPR-B, seems to be able to mediate the inhibitory action of ANP on TNF-α-
induced up-regulation of CAM, too. 
3.1.3 Inhibition of TNF-α-induced activation of NF-кB by ANP 
 
TNF-α mainly induces adhesion molecule expression by activating DNA binding 
activity of the proinflammatory transcription factor NF-κB (Collins et al. 1995). 
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Especially the regulation of ICAM-1 and E-selectin is known to be mediated at a 
transcriptional level via activation of this transcription factor (Karin 1999). As 
demonstrated above, ANP reduces TNF-α-induced CAM expression on a 
transcriptional level as shown by RT-PCR of CAM. Therefore the following 
experiment aimed to elucidate if ANP mediates its inhibitory action on TNF-α-
induced adhesion molecule expression via the transcription factor NF-κB. 
Electrophoretic mobility shift assays for NF-κB were performed as follows. 
 
3.1.3.1 Characterization of TNF-α-induced NF-κB activation 
 
NF-κB activation after TNF-α treatment  
 
First a time- and concentration-course (figure 14 and 15) for TNF-α-induced NF-κB 
activation was performed to establish the experimental procedure for further 
electrophoretic mobility shift assays. 
 
As shown in figure 14, TNF-α-activated NF-κB DNA binding activity was maximal at 
60 min.  
 
figure 14: Time course TNF-α 
Cells were either left untreated (Co) or treated with TNF-α (10 ng/ml) for 15 min up to 90 min. 
Results show one representative EMSA out of three independent experiments. 
 
The concentration for TNF-α of 10 ng/ml, was shown to be most suitable to stimulate 
NF-κB DNA binding activity (figure 15). 
figure 15: Concentration course TNF-α 
Cells were treated with TNF-α in different concentrations (1-100 ng/ml) for 1 h. Results show one 
representative EMSA out of three independent experiments. 
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0 15    30    60    90    time after treatment with TNF-α [min]
NF-κB DNA complex
NF-κB DNA complex
RESULTS 
 62
Supershift analysis of NF-κB 
 
In the following experiment the composition of the two NF-κB bands was investigated 
by supershift analysis. The faster migrating band represents a homodimer of two p50 
subunits, whereas the slower migrating band is a p50/p65 heterodimer. This was 
shown due to the fact that the faster migrating band was supershifted only by an anti-
p50 antibody, whereas the slower migrating band was supershifted by both an anti-50 
as well as by an anti-p65 antibody. Excess of unlabeled NF-κB or AP-2 binding 
sequence to binding reactions of TNF-α-treated cells served as specificity control of 
EMSA (figure 16). 
 
figure 16: Supershift analysis of NF-κB 
Supershift experiments employing specific antibodies against the NF-κB subunits p50 and p65 were 
performed in untreated or TNF-α-activated HUVEC (10 ng/ml, 1 h). Specificity of the binding 
reaction was assessed by using an excess of unlabeled NF-κB or AP-2 binding sequence to binding 
reactions of TNF-α-treated cells. One representative out of two independent experiments from 
different cell preparations with similar results is shown.  
 
3.1.3.2 Effect of ANP on TNF-α-induced activation of NF-κB 
 
In order to investigate whether ANP affects NF-κB, the transcription factor mainly 
responsible for the induction of CAM, the effect of ANP on TNF-α-induced DNA 
binding activity of NF-κB was investigated by EMSA. 
 
Treatment of HUVEC with TNF-α (10 ng/ml) resulted in a marked activation of NF-
κB DNA binding activity after 1 h of stimulation, as assessed by EMSA (figure 17). 
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Cotreatment of the cells with TNF-α and ANP (10-8-10-6 mol/L) significantly reduced 
NF-κB binding activity (figure 17). ANP alone (10-6 mol/L) significantly increased 
basal NF-κB activity (figure 17).  
 
 
figure 17: Effect of ANP on TNF-α-induced activation of NF-κB 
Cells were either left untreated (Co) or treated with TNF-α (10 ng/ml) for 1 h. ANP was added to the 
cells alone (10-6 mol/L for 1 h) or 30 min before (10-8-10-6 mol/L) TNF-α. After 1 h NF-κB EMSA 
was performed as described under Materials and methods. Using SP-1 probes served as a loading 
control (left panel). Data in the left panel represent one representative out of five independent 
experiments from different cell preparations with similar results. Data in the right panel show 
phosphorimaging analysis of EMSA experiments and are expressed as percentage of values for TNF-α 
treatment only. Data represent means ± S.E.M. out of three independent experiments from different 
cell preparations with *** p<0.001, ** p<0.01, * p<0.05 significantly different compared to the values 
seen in TNF-α-activated cells and + p<0.05 significantly different compared to untreated controls, 
whereby TNF-α was set as 100%. 
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3.1.3.3 Effect of 8-Br-cGMP on TNF-α-induced activation of NF-κB 
 
In order to determine whether the inhibitory effect of ANP on NF-κB is mediated by 
cGMP, the cell-permeable cGMP analogue, 8-Br-cGMP, was used in the same 
experimental setting as for ANP. 
 
Cotreatment of the cells with TNF-α and 8-Br-cGMP (10-4-10-3 mol/L) significantly 
reduced NF-κB DNA binding activity (figure 18), suggesting a participation of the 
guanylyl-cyclase-coupled NPR-A receptor in signal transduction by ANP. 
 
 
            DLU: density light unit 
 
 
figure 18: Effect of 8-Br-cGMP on TNF-α-induced activation of NF-κB 
Cells were either left untreated (Co) or treated with TNF-α (10 ng/ml) in the presence or absence of 8-
Br-cGMP (10-4 and 10-3 mol/L), which was added to the cells 30 min before TNF-α. Data represent 
one representative out of three independent experiments from different cell preparations with similar 
results (left panel). Data in the right panel show phosphorimaging analysis of EMSA experiments and 
are expressed as percentage of values for TNF-α treatment only. Data represent means ± S.E.M. out of 
three independent experiments from different cell preparations with ** p<0.01, * p<0.05 significantly 
different compared to the values seen in TNF-α-activated cells.  
 
3.1.3.4 Effect of CNP on TNF-α-induced activation of NF-κB 
 
As shown under 3.1.3.3 the guanylyl-cyclase-coupled NPR-A receptor is able to 
mediate the inhibition of ANP on TNF-α-induced NF-κB activation. In order to 
demonstrate whether the other guanylyl-cyclase-coupled receptor, NPR-B, is also 
involved in mediating the inhibitory property of ANP on TNF-α-induced NF-κB up-
regulation, the effect of the specific NPR-B ligand, CNP was also tested in EMSA of 
NF-κB. 
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CNP alone had no effect on NF-κB activity, whereas CNP dose-dependently (10-810-6 
mol/L) inhibited TNF-α-induced activation of NF-κB (figure 19). Therefore the 
guanylyl-cyclase-coupled NPR-B receptor also mediates the inhibitory property of 
ANP on TNF-α-induced NF-κB up-regulation. 
 
figure 19: Effect of CNP on TNF-α-induced activation of NF-κB 
Cells were either left untreated (Co) or treated with TNF-α (10 ng/ml) alone for 1 h or with TNF-α 
after 30 min pretreatment with CNP (10-8-10-6mol/L). Data show one representative out of three 
independent experiments from different cell preparations (left panel). Data in the right panel show 
phosphorimaging analysis of EMSA experiments and are expressed as percentage of values for TNF-α 
treatment only. Data represent means ± S.E.M. out of three independent experiments from different 
cell preparations with ** p<0.01 significantly different compared to the values seen in TNF-α-
activated cells.  
 
3.1.4 ANP treatment attenuates TNF-α-induced nuclear 
translocation of NF-κB subunits. 
 
As described above, TNF-α induces adhesion molecule expression via the 
proinflammatory transcription factor NF-κB. In unstimulated cells, the predominant 
form of NF-κB is present in the cytoplasm as a heterodimer of p50 and p65 subunits 
complexed with inhibitory IκB proteins. Upon stimulation IκB is phosphorylated and 
degraded, releasing NF-κB and thus allowing its translocation to the nucleus where it 
promotes the transcription of respective genes (Karin 1999). The next question we 
asked was how ANP is able to mediate reduced NF-κB DNA binding activity. One 
possibility is through inhibition of the translocation of NF-κB into the nucleus. 
Therefore in the following experiments especially the translocation of NF-κB (p65 
subunit) was assessed by immunocytochemistry and Western blot analysis of both, the 
nuclear and the cytosolic fraction of HUVEC. 
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3.1.4.1 Immunocytochemistry of p65 
 
In order to investigate whether the reduced NF-κB DNA binding activity in ANP-
treated cells shown by EMSA experiments is associated with a decreased translocation 
of NF-κB, immunocytochemistry of the p65 subunit was performed. Staining of the 
p65 subunit in indeed showed that ANP abrogated the TNF-α-induced translocation of 
NF-κB into the nucleus (figure 20): TNF-α-treated cells showed a distinct 
fluorescence of the nucleus, indicating p65 localization, compared to cytosolic staining 
of untreated cells. Pretreatment with ANP resulted in a reduced number of cells with 
translocated p65 (figure 20). 
 
 
figure 20: ANP attenuates translocation of the p65 subunit of NF-κB 
HUVEC were cultured in either medium alone (Co) or in medium containing TNF-α (10 ng/ml) in the 
presence or absence of ANP (10-6 mol/L, 30 min pretreatment) for 1 h. Cells were permeabilized and 
stained with FITC-labeled antibody as described under Materials and methods. The pictures show 
representative photographs out of three independent experiments from different cell preparations 
(original magnification 200-fold). 
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3.1.4.2 Influence of ANP on nuclear translocation of p50 and p65  
 
The results presented above were confirmed by Western blots performed with nuclear 
and cytosolic extracts of cells treated either with TNF-α alone or with TNF-α after 
pretreamtent with ANP (10-8-10-6 mol/L).  
ANP significantly inhibited the TNF-α-induced translocation of p65 and p50 into the 
nucleus (figure 21). Probing the blots with SP-1 and G-actin antibodies served as 
loading controls. ANP treatment alone (10-6 mol/L) significantly increased p65 nuclear 
translocation (figure 21). 
 
 
figure 21: ANP effects on cytosolic and nuclear levels of p50 and p65 
Cells were either left untreated (Co) or treated with TNF-α (10 ng/ml) for 1 h. ANP was added to the 
cells alone (10-6 mol/L for 1 h) or in combination (10-8-10-6 mol/L) with TNF-α (30 min pretreatment). 
Western blots of cytosolic and nuclear fractions were performed as described under Materials and 
methods with antibodies against p50 and p65. Data in the upper panel show one representative out of 
three independent Western blot experiments from different cell preparations with similar results in 
each case. Histograms in the lower panels show densitometric evaluation of Western blots and are 
expressed as x-fold of values for TNF-α treatment only. Data represent means ± S.E.M. out of three 
independent experiments from different cell preparations with ** p<0.01, * p<0.05 significantly 
different compared to the values seen in TNF-α-activated cells and + p<0.05 significantly different 
compared to untreated controls. 
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3.1.5 Influence of ANP on IκB isoforms 
 
A crucial step in the activation of NF-κB by TNF-α is the rapid phosphorylation and 
degradation of the cytoplasmic inhibitor protein IκB, existing as IκB-α, -β, and -ε 
isoform. Because it could be demonstrated that ANP reduces the nuclear translocation 
of p65 subunit (see 3.1.4), it was now investigated whether ANP is able to influence 
the TNF-α-induced phosphorylation and degradation of IκB-α. For detection of the 
phosphorylated IκB-α an antibody specifically detecting phosphorylated IκB-α was 
used in Western blot analysis. Besides the effect of ANP on IκB-α phosphorylation its 
effect on degradation of all three isoforms induced by TNF-α was determined using 
specific antibodies detecting IκB-α, IκB-β, and IκB-ε isoforms. 
 
3.1.5.1 Influence of ANP on IκB-α phosphorylation 
 
A marked increase of phosphorylated inhibitor protein (IκB) was detected 
subsequently to TNF-α treatment (figure 22). Cotreatment of the cells with TNF-α and 
ANP, however, did not have any influence on the phosphorylation degree of IκB-α 
compared to TNF-α treatment only. 
 
 
figure 22: Effect of ANP on TNF-α-induced IκB-α phosphorylation 
HUVEC were treated with TNF-α (10 ng/ml) in the presence or absence of ANP (10-6 mol/L; 30 min 
before TNF-α) for the indicated times. Data in the left panel show one representative out of three 
independent Western blots from different cell preparations. Graph shows densitometric evaluation of 
Western blots whereby data are expressed as x-fold of values for TNF-α treatment only. 
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3.1.5.2 Influence of ANP on degradation of IκB isoforms  
 
As described under 3.1.5.1 no effect of ANP on TNF-α-induced phosphorylation of 
IκB was detectable. In the next step it was investigated by Western blot, whether ANP 
affects TNF-α-induced degradation of the three isoforms of IκB. Time-course 
experiments were performed using antibodies detecting IκB-α, IκB-β, and IκB-ε. 
Probing the blots with α-tubulin antibodies served as loading control (figure 23). 
 
Pretreatment of the cells with ANP (10-6 mol/L) did not attenuate the TNF-α-induced 
degradation rate of IκB-α and IκB-β, whereas it delayed the degradation of IκB-ε. 
Interestingly, resynthesis of IκB-α after degradation was significantly elevated in 
ANP-pretreated cells (figure 23). 
 
figure 23: Effects of ANP on degradation of IκB isoforms 
HUVEC were treated with TNF-α (10 ng/ml) alone or in combination with ANP (10-6 mol/L, 30 min 
pretreatment) for the indicated times. The upper panel shows representative blots out of three 
independent experiments from different cell preparations, each. Densitometric evaluation of Western 
blots is shown in the lower graphs whereby data are expressed as x-fold of values for TNF-α. Data 
represent means ± S.E.M. out of five independent experiments from different cell preparations with 
** p<0.01, * p<0.05 significantly different compared to the values seen in TNF-α-activated cells. 
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3.1.5.3 Influence of ANP on expression of IκB-α, - β, and -ε isoforms 
 
The observed increased resynthesis of IκB-α after ANP treatment led to the suggestion 
that ANP may be able to induce the expression of IκB isoforms. Further Western blot 
experiments with ANP-treated cells were performed in order to confirm this 
hypothesis.  
 
As seen in figure 24, HUVEC stimulated with ANP showed significantly increased 
expression of IκB-α and IκB-ε. This inducing effect of ANP could not be observed for 
the IκB-β isoform. 
 
figure 24: ANP induces expression of IκB-α and -ε 
Cells were treated with ANP (10-6 mol/L) for the indicated times. Western blots using antibodies 
against IκB-α, -β, -ε, and α-tubulin were performed as described under Materials and methods. Data 
in the upper panel show one representative out of four independent experiments from different cell 
preparations. Graph shows densitometric evaluation of Western blots whereby data are expressed as x-
fold of values for IκB-α signal intensities at time point 0 min. Data represent means ± S.E.M. out of 
four independent experiments from different cell preparations with ** p<0.01, * p<0.05 significantly 
different compared to the values seen in control cells. 
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3.1.6 Transcriptional induction of IκB-α by ANP 
 
As shown by Western blot ANP is able to induce IκB-α. In order to demonstrate 
whether the IκB induction is mediated on the transcriptional level, IκB-α levels were 
determined after pretreating cells with actinomycin D, a known inhibitor of 
transcription.  
 
3.1.6.1 IκB-α expression in the presence of actinomycin D 
 
ANP elevated IκB-α levels only in the absence of actinomycin D (figure 25). This 
indicates that in case of inhibiting the transcription by actinomycin D, ANP is no 
longer able to induce IκB-α protein expression. Thus ANP acts on a transcriptional 
level to increase IκB-α protein. 
 
 
 
figure 25: Effect of ANP on IκB-α induction in the presence of actinomycin D. 
HUVEC were treated with ANP (10-6 mol/L) or actinomycin D (2 µmol/L) for the indicated times or 
with ANP after pretreatment (30 min) of the cells with actinomycin D. Data in the left panel show one 
representative out of four independent experiments from different cell preparations. Graph shows 
densitometric evaluation of Western blots whereby data are expressed as x-fold of values for IκB-α 
signal intensities at time point 0 min of the respective blot. Data represent means ± S.E.M. out of four 
independent experiments from different cell preparations. *** p<0.001, ** p<0.01 significantly 
different compared to the values at 0 min. 
 
3.1.6.2 Influence of ANP on IκB-α mRNA expression 
 
In the following experiments the observations described under 3.1.6.1 were confirmed 
by investigating the mRNA levels of HUVEC after treatment with ANP (figure 26). 
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As shown in figure 26, treatment of the cells with ANP (10-6 mol/L) showed after 10 
min slightly and after 20 min significantly elevated IκB-α mRNA levels. 
 
figure 26: Effect of ANP on IκB-α  mRNA expression 
HUVEC were treated with ANP (10-6 mol/L) for the indicated times. RNA was isolated and IκB-α and 
GAPDH mRNA was estimated by RT-PCR. Data show one representative out of three independent 
experiments from different cell preparations. Densitometric evaluation of ethidium bromide stained 
gels is shown whereby data are expressed as x-fold of values of cells at time point 0 min normalized 
for GAPDH. ** p<0.01 significantly different compared to the values seen at 0 min. 
 
3.1.7 Influence of ANP on the activator protein 1 (AP-1) 
 
Another transcription factor activated by TNF-α is the activator protein-1. In order to 
determine whether the inhibitory action of ANP is specific for TNF-α-induced NF-κB 
activity, the effect of ANP on AP-1 activity and TNF-α-induced AP-1 activity was 
examinated. 
[In another study performed by Nicole Bildner, a coworker in the group of Prof. 
Vollmar, this issue is worked out in context of HO-1 induction by ANP via 
upregulation of AP-1. With reference to the work of Nicole Bildner the following 
results are given in a short version.] 
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3.1.7.1 Characterization of TNF-α-induced AP-1 activity 
 
AP-1 activation after TNF-α treatment 
 
First a time- and concentration-course (figure 27 and 28) for TNF-α-induced AP-1 
activation was performed to establish the experimental procedure for further 
electrophoretic mobility shift assays. 
 
As shown in figure 27, TNF-α-induced AP-1 DNA binding activity was detectable 
after 30 up to 60 min.  
 
figure 27: Time course TNF-α 
Cells were either left untreated (Co) or treated with TNF-α (10 ng/ml) for 15 min up to 90 min. 
Results show one representative EMSA out of three independent experiments. 
 
A suitable concentration for stimulation of AP-1 DNA binding activity was 10 ng/ml 
TNF-α as shown by the following EMSA (figure 28).  
 
 
figure 28: Concentration course TNF-α 
Cells were treated with TNF-α in different concentrations (1-100 ng/ml) for 1 h. Results show one 
representative EMSA out of three independent experiments. 
 
Supershift analysis of AP-1 
 
In the next experiment the composition of AP-1 was investigated by supershift 
analysis. It was demonstrated that the AP-1 complex is composed of c-jun and c-fos 
subunits, because after addition of an anti-c-jun as well as an anti-c-fos antibody the 
signal intensity of the AP-1 band decreased (figure 29). 
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figure 29: Supershift analysis of AP-1 
Supershift experiments employing specific antibodies against the AP-1 subunits c-jun and c-fos were 
performed in untreated or TNF-α-activated HUVEC (10 ng/ml, 1 h). One representative out of three 
independent experiments from different cell preparations with similar results is shown.  
 
3.1.7.2 Effect of ANP on TNF-α-induced activation of AP-1  
 
To investigate whether ANP affects TNF-α-induced DNA binding activity of AP-1 
electrophoretic mobility shift assay was performed . 
 
Treatment of HUVEC with TNF-α (10 ng/ml) resulted in a marked activation of AP-1 
DNA binding activity after 1 h of stimulation, as assessed by electrophoretic mobility 
shift assay (figure 30). ANP alone (10-6 mol/L) significantly increased basal AP-1 
activity (figure 30). Interestingly cotreatment of the cells with TNF-α and ANP (10-8-
10-6 mol/L) had no effect on AP-1 DNA binding activity (figure 30).  
 
 
 
figure 30: Effect of ANP on TNF-α-induced AP-1 activity 
Cells were either left untreated (Co) or treated with TNF-α (10 ng/ml) for one hour. ANP was added 
to the cells alone (10-6 mol/L for 1 h) or 30 min before (10-8-10-6 mol/L) TNF-α (1 h). EMSA was 
performed as described under Materials and methods. Data represent one representative out of three 
independent experiments from different cell preparations with similar results. 
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3.1.7.3 Effect of ANP on AP-1 activity 
 
Due to the observed induction of basal AP-1 in figure 30 the following EMSA aimed 
to determine the influence of ANP alone on transcriptional activity of AP-1. Therefore 
a time (figure 31) and concentration (figure 32) course for ANP was performed. 
 
The time course shown in figure 31 demonstrated that the stimulation of AP-1 DNA 
binding activity was maximal after 15 and 90 min of treatment with ANP suggesting a 
biphasic time course for ANP-induced AP-1 activity. 
 
 
figure 31: Time course ANP 
Cells were either left untreated (Co) or treated with ANP (10-6 mol/L) for 15 min up to 120 min. 
EMSA was performed as described under Materials and methods. Results show one representative 
EMSA out of three independent experiments. 
 
The results in figure 32 show that ANP is dose-dependently (10-7-10-6 mol/L) able to 
induce the DNA binding activity of AP-1. 
 
figure 32: Concentration course ANP 
Cells were treated with ANP in different concentrations (10-8-10-6 mol/L) for 1 h. Results show one 
representative EMSA out of three independent experiments. 
3.1.7.4 Blocking of AP-1 by oligonucleotide decoys 
 
In order to show a causal relationship between HO-1 induction, observed by Nicole 
Bildner, and the induction of AP-1 detected by EMSA, the DNA protein binding was 
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blocked by the use of AP-1 oligonucleotide decoys and subsequently Western blot for 
HO-1 (Nicole Bildner) and EMSA for AP-1 was performed. HUVEC were transfected 
with decoys using an EffecteneTM transfection kit (Qiagen) and EMSA was performed 
as usual. 
 
The results given in figure 33 demonstrate that it was possible to block AP-1 DNA 
binding activity by specific AP-1 decoys. The transfection with scrambled decoys did 
not result in decreased DNA binding activity of AP-1 and served as control of 
specificity. 
 
figure 33: Blocking of AP-1 by oligonucleotide decoys 
Cells were either left untreated (Co) or treated with ANP (10-8-10-7 mol/L) for 1 h after a 4 h 
transfection of cells with AP-1 decoy or scrambled decoy. EMSA was performed as described under 
Materials and methods. Specificity of the binding reaction was assessed by using an excess of 
unlabeled AP-1 or AP-2 DNA oligonucleotides to binding reactions of TNF-α-treated cells. Data 
represent one representative out of three independent experiments from different cell preparations with 
similar results. 
 
3.1.7.5 Inhibition of AP-1 DNA binding activity by U0126 
 
Another possibility to demonstrate the causal link between HO-1 induction and the 
observed AP-1 induction by ANP is to inhibit the activity of AP-1 by the use of 
U0126, a specific inhibitor of AP-1 activity. After incubation of cells with U0126 for 
30 min EMSA was performed as usual. 
 
Figure 34 shows that it was possible to inhibit the DNA binding activity of AP-1, 
because the ANP induced AP-1 activation was no longer detectable after treatment of 
the cells with U0126 (figure 34). 
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figure 34: Inhibition of AP-1 DNA binding activity by U0126 
After preincubation of cells with U0126 for 30 min cells were either left untreated (Co) or treated with 
ANP (10-7-10-6 mol/L) for 1 h. EMSA was performed as described under Materials and methods. 
Data represent one representative out of three independent experiments from different cell 
preparations with similar results. 
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3.2 Cytoskeleton  
3.2.1 Inhibitory properties of ANP on TNF-α-induced 
permeability in HUVEC 
 
Besides the observation that ANP is able to reduce TNF-α-induced E-selectin and 
ICAM-1 expression, effects of ANP on TNF-α-induced cytoskeleton changes were 
investigated in the following experiments. TNF-α exerts several effects that facilitate 
the formation of an atheromatous plaque. For example it increases endothelial cell gap 
formation. As a result of TNF-α-induced cell damage an increased vascular 
permeability is commonly attributed to the reorganization of F-actin filaments 
followed by contraction of cells and formation of intercellular gaps (Brett et al. 1989; 
Lum and Malik 1996; van Hinsbergh 1997; Wojciak-Stothard et al. 1998). 
 
In order to test the effects of ANP on this TNF-α-mediated permeability- and 
cytoskeleton-changes, the subsequent experiments were performed.  
 
Endothelial permeability was assessed by a FITC-albumin permeability assay as 
described under Materials and methods. Treatment of HUVEC with TNF-α led to an 
increase in endothelial permeability as indicated by an increased FITC-albumin flux 
through endothelial monolayers (figure 35 A+B). ANP significantly abrogated the 
TNF-α-induced increase in permeability, whereas ANP alone showed no effect on 
albumin flux (figure 35 A+B). In order to stress the observed effects of ANP data were 
recalculated by substraction of permeability of control cells and in figure 35 panel B 
percentage of TNF-α-induced permeability is shown, whereby TNF-α was set 100%. 
 
figure 35: ANP inhibits TNF-α induced increase in HUVEC permeability 
Panel A: HUVEC in transwell chambers were either left untreated or treated with TNF-α (25 ng/ml) 
alone or in combination with ANP (10-6 mol/L) for 24 h whereby ANP was added to the cells 30 min 
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before TNF-α. Permeability of FITC-labeled BSA was determined as described in Materials and 
methods and albumin flux of TNF-α treated cells were referred to as 100%. Panel B: Data show 
percentage of TNF-α-induced permeability after substraction of permeability of control cells and 
TNF-α was set as 100%, treatment of cells see panel A. Data show mean ± S.E.M. of three different 
experiments (different cell preparations) prepared in triplicates or quadruplets. **p<0.01 represents 
significant difference from values in TNF-α-activated cells. 
 
3.2.2 Influence of ANP on TNF-α-induced morphological 
changes and stress fiber formation  
 
In the subsequent morphological investigations the influence of ANP (10-6 mol/L) on 
TNF-α-induced cytoskeleton changes was examined either after Haemacolor® staining 
(figure 36) or after intracellular staining of F-actin stress fiber bundles with a specific 
F-actin binding rhodamine phalloidin dye (figure 37). 
 
3.2.2.1 Morphological investigations 
 
As demonstrated in figure 36, untreated HUVEC were well spread and showed a 
typical cobblestone morphology. After treatment of the cells with TNF-α, cells 
started to retract, elongate, and form intercellular gaps. ANP almost completely 
abrogated these changes in HUVEC morphology (figure 36). 
 
 
 
 
 
 
 
 
figure 36: Effect of ANP on TNF-α induced morphological changes 
Confluent HUVEC monolayers were cultured in either medium alone (Co) or in medium containing 
TNF-α (10 ng/ml) in the presence or absence of ANP (10-6 mol/L) for 1 h (pretreatment with ANP for 
30 min). Cells were stained as described in Materials and methods. The pictures show representative 
photographs out of four independent experiments from different cell preparations (original 
magnification 200-fold). 
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3.2.2.2 Stress fiber formation 
 
The results of the intracellular staining for F-actin are shown in figure 37. After 
permeabilisation of HUVEC with Triton X-100, the intracellular cytoskeleton 
component F-actin was stained with rhodamin phalloidin, a specific antibody detecting 
only polymerized actin. 
 
In untreated, confluent HUVEC monolayers F-actin was concentrated in fine F-actin 
filaments transversing the cells. As shown in figure 37, TNF-α induced changes in F-
actin organization whereby the cells showed an increase and thickening of actin 
bundles and the formation of stress fibers. Intercellular gaps and cell retraction were 
indicated by large unstained areas of the image. Cotreatment of the cells with ANP 
inhibited TNF-α-induced alterations in actin distribution (figure 37). 
 
 
figure 37: ANP attenuated TNF-α-induced stress fiber formation in HUVEC 
HUVEC were either untreated (Co) or activated with TNF-α (10 ng/ml) with or without ANP (10-6 
mol/L) for 30 min. Data show one representative out of three independent experiments from different 
cell preparations (original magnification 400-fold). The lower panel shows a detailed confocal 
microscopic picture of one untreated, TNF treated or TNF and ANP treated cell. 
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3.2.2.3 Investigations on F-actin content 
 
For quantification of the given results, HUVEC were again stained for F-actin and the 
intracellular F-actin content was determined by methanolic extraction and 
quantification of bound rhodamin phalloidin in a fluorescence spectral photometer. In 
order to investigate the receptor specificity of the observed ANP effect the cell 
permeable analogue of cGMP, 8-Br-cGMP was used in the same experimental 
settings. 
 
TNF-α led to a strong increase of cellular F-actin content. Treatment of the cells with 
ANP (10-8-10-6 mol/L) significantly inhibited TNF-α-induced actin polymerization. 
ANP in a concentration of 10-6 mol/L alone did not significantly affect F-actin content 
(figure 38). 
 
The second messenger analogue 8-Br-cGMP mimicked the effect of ANP on the TNF-
α-induced increase in F-actin content (figure 38). 
 
In order to determine whether ANP-induced changes in F-actin content were related to 
different expression of actin upon treatment with ANP, whole actin content was 
determined by performing Western blots of G-actin. The amount of actin was not 
different in cells treated with TNF-α + ANP compared to cells treated with TNF-α 
(figure 38, insert Western blot). 
 
figure 38: Effect of ANP and 8-Br-cGMP on F-actin polymerization. 
Cells were either left untreated (Co) or treated with TNF-α (10 ng/ml) for 1 h. ANP (10-10-10-6 mol/L) 
or 8-Br-cGMP (10-3 and 10-4 mol/L) was added to the cells alone or 30 min before TNF-α. Data are 
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expressed as percentage of mean fluorescence with 100% representing values for TNF-α treatment 
only. Data show mean ± S.E.M. of three to five independent experiments from different cell 
preparations, each performed in triplicates. *** p<0.001 and ** p<0.01 represent significant 
differences compared to the values seen in TNF-α-activated cells. The inserted Western blot shows 
total actin of cells treated with TNF-α (10 ng/ml) for 1 h with or without 30 min ANP pretreatment 
(10-8-10-6 mol/L).  
 
3.2.3 Molecular mechanism involved in the inhibitory action of 
ANP on TNF-α-induced cytoskeleton changes 
 
The TNF-α-induced reorganization of F-actin and therefore the formation of stress 
fibers, is associated with the polymerization of G-actin into F-actin fibers (Wojciak-
Stothard et al. 1998). Phosphorylation of the heat shock protein HSP27 has previously 
been shown to regulate actin polymerization (Landry and Huot 1995) and to contribute 
to stress fiber formation in endothelial cells (Huot et al. 1997). The next investigations 
therefore aimed to determine the influence of ANP on TNF-α-induced 
phosphorylation of HSP27 and to examine whether ANP influences actin 
polymerization via this pathway. 
The phosphorylation of HSP27 was examined by Western blot using a specific anti 
phospho HSP27 antibody (figure 39). 
 
3.2.3.1 Inhibition of HSP27 phosphorylation by ANP 
 
Treatment of the cells with TNF-α (0-120 min) led to a marked phosphorylation of 
HSP27 (figure 39, upper Western blot), whereas ANP significantly inhibited TNF-α- 
induced phosphorylation of HSP27. Changes in phosphorylation of HSP27 were not 
due to different amounts of HSP27 as shown by Western blot using an antibody 
against HSP27 (figure 39, lower Western blot). 
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figure 39: Influence of ANP on TNF-α-induced phosphorylation of HSP27 
HUVEC were treated with TNF-α (10 ng/ml) alone or in combination with ANP (10-6 mol/L) for the 
indicated times. HSP27 served as loading controle and is shown in the lower Western blot. One 
representative out of three independent experiments from different cell preparations is shown, each. 
The lower panel shows densitometric evaluation of three experiments expressed as x-fold increase vs. 
0 min. ** p<0.01 represent significant differences compared to TNF-α treatment alone. 
 
3.2.3.2 Involvement of p38 MAPK in cytoskeleton changes 
 
HSP27 is phosphorylated by the mitogen activated protein kinase activated protein 
kinase-2 (MAPKAPK-2) (Obata et al. 2000) and therefore represents a downstream 
target of the p38 mitogen activated protein kinase (MAPK). The role of p38 MAPK 
for actin polymerization has been shown in oxidant-stress induced stress fiber 
formation (Huot et al. 1997). In order to investigate a potential role for p38 MAPK in 
the described signal transduction pathway, the effect of a specific p38 MAPK 
inhibitor, SB203580, on TNF-α-induced cytoskeleton changes was tested in the 
following experiments. 
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TNF-α-induced formation of stress fibers was abrogated by SB203580 as shown by 
actin staining (figure 40). 
 
 
 
 
 
figure 40: Effect of specific p38 inhibitor SB203580 on stress fiber formation 
Cells were either left untreated (Co) or treated with TNF-α (10 ng/ml) in the presence or absence of 
SB203580 (5x10-6 mol/L) for 30 min. Cells were permeabilized and stained with rhodamine-
phalloidin. Data show one representative out of four independent experiments from different cell 
preparations (original magnification 200-fold). 
 
As demonstrated in figure 41, SB203580 alone did not affect basal F-actin content, 
whereas it significantly reduced TNF-α-induced F-actin formation. 
 
 
 
figure 41: Effect of specific p38 inhibitor SB203580 on F-actin content 
HUVEC were cultured in either medium alone (Co), in medium with SB203580 (10-5 mol/L), or in 
medium containing TNF-α (10 ng/ml) in the presence or absence of SB203580 (10-5 mol/L). F-actin 
was quantified by fluorescence photometry. Values for TNF-α treatment only were referred to as 
100%. Data show mean ± S.E.M. of four independent experiments from different cell preparations, 
each performed in triplicates. *** p<0.001 represent significant differences compared to the values 
seen in TNF-α-activated cells. 
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3.2.3.3 Involvement of p38 MAPK in TNF-α-induced permeability 
 
As shown under 3.2.3.2 the p38 MAPK is involved in the signal transduction of TNF-
α-induced cytoskeleton changes as demonstrated by the use of the specific p38 MAPK 
inhibitor SB203580. Besides this result it was investigated whether the p38 MAPK is 
additionally participating in the TNF-α-induced permeability signal transduction. 
Therefore the specific p38 MAPK inhibitor SB203580 was used in the same 
experimental settings as described under 3.2.1 for ANP to determine the effect of 
SB203580 on TNF-α-induced endothelial permeability (figure 42 A+B). 
 
SB203580 alone did not affect endothelial permeability. But SB203580 abrogated 
TNF-α-induced elevated BSA flux (figure 42 A+B). In order to stress the observed 
effects of SB203580 data were recalculated by substraction of permeability of control 
cells and in figure 42 panel B percentage of TNF-α-induced permeability is shown, 
whereby TNF-α was set as 100%. 
  
 
figure 42: Effect of specific p38 inhibitor SB203580 on permeability 
Panel A: HUVEC in transwell chambers were either left untreated or treated with TNF-α (25 ng/ml) 
alone or in combination with SB203580 (5x10-6 mol/L for 24 h). Permeability of FITC-labeled BSA 
was determined as described in Materials and methods and albumin flux of TNF-α treated cells 
were referred to as 100%. Panel B: Data show percentage of TNF-α-induced permeability after 
substraction of permeability of control cells and TNF-α was set as 100%, treatment of cells see panel 
A. Data show mean ± S.E.M. of three different experiments (different cell preparations) prepared in 
triplicates or quadruplets. ** p<0.01 represents significant difference from values in TNF-α-activated 
cells. 
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3.2.3.4 Inhibition of TNF-α-induced phosphorylation of p38 MAPK by 
ANP 
 
These results suggest the participation of p38 MAPK in the signal transduction of 
ANP mediated reduction of TNF-α-induced changes in permeability and cytoskeleton. 
Due to the causal role of TNF-α-induced p38 MAPK activation for actin 
polymerization, an effect of ANP on p38 MAPK was investigated. MAPK activation 
was measured by immunoblotting with epitope-specific anti-phosphotyrosine-
antibodies to determine MAPK phosphorylation (figure 43). 
 
ANP significantly reduced TNF-α-mediated activation of p38 MAPK as shown by 
Western blot (figure 43, upper Western blot). ANP did not affect the amount of total 
p38 MAPK (figure 43, lower Western blot).  
 
 
figure 43: Influence of ANP on TNF-α-induced phosphorylation of p38 
HUVEC were treated with TNF-α (10 ng/ml) in the presence or absence of ANP (10-6 mol/L) for the 
indicated times whereas ANP was added to the cells 30 min before TNF-α. Western blot was 
performed as described under Materials and methods. The upper panel shows one representative out 
of three independent experiments from different cell preparations, each. Histogramm shows 
densitometric evaluation of signal intensities of three experiments whereby * p<0.05, ** p<0.01 
represent significant differences compared to TNF-α treatment alone. 
 
 
 
0       5   10    15    20   30     0     5     10   15     20    30   min after addition of TNF
phospho  p38
TNF + ANPTNF 
p38
fo
ld
 in
cr
ea
se
time [min]
0        10      20    30       40       50      60
14
12
10
8
6
4
2
0
* * **
**
TNF
TNF+ANP
fo
ld
 in
cr
ea
se
3.2 CYTOSKELETON  
 87 
The inhibition of p38 MAPK phosphorylation by ANP was dose-dependent as shown 
by Western blot in figure 44. 
 
 
figure 44: Dose dependent inhibition of activation of p38 by ANP 
HUVEC were either untreated (Co) or treated with TNF-α (10 ng/ml) in the presence or absence of 
ANP (10-8-10-6 mol/L) which was added to the cells 30 min before TNF-α (15 min). Western blot was 
performed as described under Materials and methods. p38 MAPK activation was shown by 
demonstrating phosphorylated p38. 
 
3.2.3.5 Mechanism of reduced p38 MAPK activation by ANP 
 
In order to clarify a possible mechanism by which ANP reduces TNF-α-induced p38 
MAPK activation two potential pathways were investigated. First the influence of 
ANP on the known upstream MAPKK of p38 MAPK, MKK 3/6, was investigated by 
Western blot (figure 45). 
 
ANP had no influence on TNF-α-induced activation of MKK3/6 (figure 45). 
 
figure 45: ANP treatment does not affect MKK3/6 activation 
Cells were activated with TNF-α (10 ng/ml) with or without ANP (10-8-10-6 mol/L) for the indicated 
times. MKK3/6 activation was determined by Western blot using an antibody against the activated 
form of MKK3/6. The upper panel shows one representative out of four independent experiments from 
different cell preparations. The lower panel shows the densitometric evaluation of signal intensities of 
four experiments. 
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As no effect of ANP on MKK3/6 was detectable, the second potential pathway for 
deactivating p38 MAPK was investigated. p38 MAPK can be deactivated by a dual-
specificity MAPK phosphatase (MKP), which target the two critical phosphorylation 
sites in the activation loop of MAPK. From the known MKP, MKP-1 is known to be 
responsible for the dephosphorylation of p38 (Chen et al. 2001), which could not be 
shown for MKP-2 (Chu et al. 1996) or MKP-3 (Nichols et al. 2000). Therefore the 
effect of ANP on MKP-1 protein expression was investigated by Western blot (figure 
46) and the effect of ANP on MKP-1 mRNA was examined by RT-PCR (figure 47). 
 
ANP (10-6 mol/L) significantly increased MKP-1 protein expression as early as 30 
min, whereas TNF-α alone had no effect on MKP-1 expression (figure 46). 
 
 
figure 46: ANP induces MKP-1 protein expression 
Cells were treated with ANP (10-6 mol/L) or TNF-α  (10 ng/ml) for the indicated times. MKP-1 
expression was investigated by Western blot. The blots show one representative out of four 
independent experiments from different cell preparations, each. The lower panel shows densitometric 
evaluation of signal intensities of three experiments whereby ** p<0.01 represent significant 
differences compared to the values seen at time point 0 min of the respective treatment. 
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Regulation of MKP-1 induction by ANP 
 
As shown by Western blot ANP is able to induce MKP-1 protein levels. In order to 
demonstrate if the MKP-1 induction is mediated on the transcriptional level RT-PCR 
for MKP-1 was performed as described under Materials and methods. 
  
Figure 47 demonstrates that ANP (10-6 mol/L) significantly elevated MKP-1 mRNA 
levels as early as 20 minutes and therefore suggests transcriptional regulation of 
MKP-1 induction by ANP. 
 
 
figure 47: Transcriptional upregulation of MKP-1 by ANP 
HUVEC were treated with ANP (10-6 mol/L) for the indicated times. RNA was isolated and MKP-1 
and GAPDH mRNA was estimated by RT-PCR. Data show one representative out of three 
independent experiments from different cell preparations. Densitometric evaluation of ethidium 
bromide stained gels is shown whereby data are expressed as x-fold of values of cells at time point 
0 min normalized for GAPDH. ** p<0.01 significantly different compared to the values seen at 0 min 
 
3.2.4 Causal relationship between MKP-1 induction and p38 
MAPK inhibition by ANP 
 
In order to investigate if MKP-1 upregulation during ANP pretreatment does indeed 
contribute to a p38 inhibition, it was tested if addition of ANP simultaneously with 
TNF- α resulted in the same inhibitory action on p38.  
 
A significant p38 inhibition by ANP occurred significantly only after 30 min or later 
(figure 48). This result indicates that preincubation with ANP (which leads to 
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increased expression of MKP-1) is indeed necessary for early inhibition of TNF-α-
induced p38 activation. 
 
 
 
 
figure 48: Involvement of MKP-1 induction in p38 inhibition 
HUVEC were treated with TNF-α (10 ng/ml) in the presence or absence of ANP (10-6 mol/L) for the 
indicated times whereby ANP was given to the cells simultaneously with TNF-α. Cells were harvested 
in the presence of phosphatase inhibitors and Western blots were performed using antibodies against 
phosphorylated and non-phosphorylated p38. The blots show one representative out of three 
independent experiments from different cell preparations, each. The lower panel shows densitometric 
evaluation of signal intensities of three blots with ** p<0.01 representing significant differences 
compared to the values seen at time point 0 min. 
 
The direct causal relationship between the MKP-1 induction by ANP and the p38 
MAPK inhibition was demonstrated by antisense-experiments.  
In a first control experiment the inhibition of MKP-1 translation after 3 h of incubation 
with antisense oligonucleotides in presence or absence of ANP (10-6 mol/L) was 
shown by Western blot (figure 49). Use of sense oligonucleotides served as control for 
specificity of the experiment (figure 49). 
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figure 49: Blocking of MKP-1 expression by antisense-oligonucleotides 
Cells were treated with ANP (10-6 mol/L) for the indicated time after transfection with antisense or 
sense oligonucleotides for MKP-1 as described under Materials and methods. MKP-1 expression 
was investigated by Western blot. The blots show one representative out of four independent 
experiments from different cell preparations, each. Data show mean ± S.E.M. of four independent 
experiments with *** p<0.001 represent significant differences compared to the values seen in control 
cells. 
 
The following Western blot of phospho p38 MAPK shows that the blockade of MKP-1 
translation by antisense-oligonucleotides leads to the abolition of the inhibitory effects 
of ANP on p38 MAPK phosphorylation (figure 50).  
figure 50: Abolition of ANP mediated p38 inhibition by blockade of MKP-1 with 
antisense-oligonucleotides 
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HUVEC were either left untreated (Co) or treated with TNF-α (10 ng/ml) in the presence or absence 
of ANP (10-6 mol/L) which was added to the cells 30 min before TNF-α (15 min) after transfection of 
cells with antisense or sense oligonucleotides for MKP-1 as described under Materials and methods. 
The upper panel shows one representative Western blot out of four independent experiments with 
similar results, each. Values for TNF-α treatment only were referred to as 1. Data show mean ± 
S.E.M. of four independent experiments with ** p<0.01 and *** p<0.001 represent significant 
differences compared to the values seen in TNF-α-activated cells. p38 MAPK activation was shown 
by demonstrating phosphorylated p38 in Western blot, detection of unphosphorylated p38 in the lower 
blot served as loading control. 
 
This result confirmes the results given in figure 48. It demonstrates that the 
transcriptional upregulation of MKP-1 by ANP is indeed necessary for early inhibition 
of TNF-α-induced p38 activation. 
 
3.3 Monocyte chemoattractant protein (MCP-1) 
 
As a proinflammatory cytokine TNF-α is able to induce the expression of chemokines, 
such as the monocyte chemoattractant protein (MCP-1). MCP-1 is a member of the CC 
chemokine subfamily and is critically involved in the recruitment of leukocytes to sites 
of the inflamed tissue, by binding to certain chemokine receptors that are expressed on 
the cell surface of several cells, such as endothelial cells, smooth muscle cells, or 
leukocytes. MCP-1 and other chemokines have been shown to play a key role in 
communication between different cells during the immune response under 
inflammatory conditions. 
 
3.3.1 ANP inhibits TNF-α-induced secretion of MCP-1  
 
In order to determine the influence of ANP on the TNF-α-induced secretion of the 
monocyte chemoattractant protein (MCP-1), secretion of MCP-1 in culture medium 
was investigated by enzyme-linked immunosorbent assay (ELISA) (figure 51). 
 
ANP pretreatment dose-dependently (10-10-10-6mol/L) reduced MCP-1 protein (figure 
51). ANP (10-6 mol/L) alone significantly elevated basal MCP-1 expression. 
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figure 51: ELISA analysis of MCP-1 protein 
MCP-1 protein expression was detected by ELISA. Cells were left untreated, TNF-α-treated (6 h), and 
TNF-α + ANP (10-11-10-6 mol/L) treated, whereby ANP was added 30 min before TNF-α. Data show 
mean percentage MCP-1 ± S.E.M. of three independent experiments from different cell preparations. 
** p<0.01 and *** p<0.001 represent significant differences compared to the values seen in TNF-α-
activated cells, whereby TNF-α was set as 100%. ++ p<0.01 represents significant differences 
compared to the values seen in control cells.  
 
3.3.2 Receptor specificity of the ANP effect on MCP-1  
 
In order to clarify the receptor specificity of the inhibitory effect of ANP on TNF-α-
induced expression of MCP-1, the following substances were tested for their influence 
on the TNF-α-induced MCP-1 release: The cell-permeable analogue of cGMP, 8-Br-
cGMP, the specific NPR-C ligand cANF and the specific NPR-B ligand CNP. 
Experiments with the mentioned substances were carried out with TNF-α-treated cells 
by ELISA. 
 
The cell-permeable analogue of cGMP, 8-Br-cGMP, significantly reduced TNF-α-
induced MCP-1 expression in a dose-dependent manner (figure 52). 
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figure 52: Effect of 8-Br-cGMP on MCP-1 expression 
MCP-1 expression of control cells (Co) or of cells treated with TNF-α (10 ng/ml, 6 h) was determined 
by ELISA as described under Materials and Methodes. The effect of 8-Br-cGMP(10-10-10-3 mol/L) 
on the expression of MCP-1 was determined for 8-Br-cGMP added to the cells 30 min before TNF-α, 
or for 8-Br-cGMP given to the cells alone (10-3 mol/L) for 6 h. Data show mean percentage of MCP-1 
± S.E.M. of three independent experiments from different cell preparations, whereby TNF-α was set 
as 100%. *** p<0.001 and ** p<0.01 represent significant differences compared to the values seen in 
TNF-α-activated cells. 
 
As demonstrated in figure 53 the NPR-C ligand cANF did not inhibit the TNF-α-
induced MCP-1 expression, moreover it increased basal MCP-1 expression 
significantly (figure 53). 
 
figure 53: Effect of the NPR-C specific ligand cANF on MCP-1 expression 
MCP-1 expression of control cells (Co) or of cells treated with TNF-α (10 ng/ml, 6 h) was determined 
by ELISA as described under Materials and methods. The effect of cANF (10-8-10-6 mol/L) on the 
expression of MCP-1 was determined for cANF added to the cells 30 min before TNF-α, or for cANF 
given to the cells alone for 6 hours. Data show mean percentage of MCP-1 ± S.E.M. of three 
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independent experiments from different cell preparations, whereby TNF-α was set as 100%. ++ p<0.01 
represents significant differences compared to the values seen in control cells.  
 
Interestingly the specific NPR-B ligand CNP exerted similar effects like ANP. CNP 
pretreatment (10-7-10-6mol/L) of the cells significantly reduced TNF-α-induced 
MCP-1 secretion (figure 54). 
 
 
 
figure 54: Effect of CNP on MCP-1 expression 
MCP-1 expression of control cells (Co), CNP treated, or of cells treated with TNF-α (10 ng/ml, 6 h) 
was determined by ELISA as described under Materials and Methodes. The effect of CNP (10-11-  
10 -6 mol/L) on the expression of MCP-1 was determined for CNP added to the cells 30 min before 
TNF-α, or for CNP given to the cells alone (10-6 mol/L) for 6 h. Data show mean percentage of MCP-
1 ± S.E.M. of three independent experiments from different cell preparations, whereby TNF-α was set 
as 100%. * p<0.05 represent significant differences compared to the values seen in TNF-α-activated 
cells. 
 
3.3.3 Modulation of MCP-1 expression by NO 
 
These data suggest a role for cGMP and therefore for the particulate guanylyl-cyclase-
coupled NPR in the signal transduction of ANP-mediated effects. To examine if the 
soluble guanylyl-cyclase (sGC) also mediates this effect, we were interested if NO, an 
activator of the sGC affects TNF-α-induced MCP-1 production. Therefore we 
performed ELISA experiments using the NO-donor GSNO. 
 
GSNO-pretreated cells showed indeed an attenuated TNF-α-induced MCP-1 
expression (figure 55). 
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figure 55: Modulation of MCP-1 expression by NO-donor GSNO 
HUVEC were cultured in either medium alone (Co), or in medium containing TNF-α (10 ng/ml, 6 h) 
with or without pretreatment (30 min) of the cells with two concentrations of GSNO (125 and 500 
µmol/L). MCP-1 expression was detected by ELISA measurement as described under Materials and 
methods. Data show mean ± S.E.M. of three independent experiments from different cell 
preparations. * p<0.05 represent significant differences compared to the values seen in TNF-α-
activated cells, whereby TNF-α was set as 100%.  
 
These data point to an inhibitory action of NO on TNF-α-induced MCP-1 secretion 
and further supports our observations of cGMP as second messenger in the signal 
transduction. 
 
Furthermore we were interested in the potential role of TNF-α-induced NO production 
in the regulation of MCP-1 secretion. Inhibition of NO production by preincubation 
(30 min) with the NOS inhibitor, L-NNA (125 and 500 µmol/L) did not affect TNF-α-
induced MCP-1 (figure 56).  
 
figure 56: Modulation of MCP-1 expression by NOS inhibitor L-NNA  
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HUVEC were cultured in either medium alone (Co), medium containing L-NNA, or in medium 
containing TNF-α (10 ng/ml, 6 h) with or without pretreatment (30 min) of the cells with two 
concentrations of L-NNA (125 and 500 µmol/L). MCP-1 expression was detected by ELISA 
measurement as described under Materials and methods. Data show mean ± S.E.M. of three 
independent experiments from different cell preparations. + p<0.05 represents significant differences 
compared to the values seen in control cells.  
 
3.3.4 ANP reduces TNF-α-induced MCP-1 mRNA expression 
 
These data show a guanylyl-cyclase-mediated inhibition of TNF-α-induced MCP-1 
secretion by ANP. The following experiments aimed to elucidate the molecular 
mechanism leading to this inhibitory action of ANP. In order to clarify whether the 
inhibition of TNF-α-induced MCP-1 secretion is regulated on a transcriptional level 
we performed semiquantitative RT-PCR.  
TNF-α (10 ng/ml) significantly induced MCP-1 mRNA in HUVEC (figure 58). ANP 
pretreatment (10-8-10-6mol/L) indeed reduced TNF-α-induced expression of MCP-1 
mRNA significantly, whereas ANP alone significantly elevated basal MCP-1 
expression (figure 58).  
 
figure 57: Dose-dependent inhibition of MCP-1 mRNA expression by ANP 
HUVEC were cultured in either medium alone (Co), medium containing ANP (10-6 mol/L) or in 
medium containing TNF-α (10 ng/ml, 3 h) with or without pretreatment (30 min) of the cells with 
various concentrations of ANP (10-8-10-6 mol/L). RT-PCR was performed as described under 
Materials and methods. Data show representative gels out of four independent experiments 
100
80
60
40
20
0
si
gn
al
 in
te
ns
ity
 [%
]
- 6        - 6            - 7         - 8   
Co TNF        ANP            TNF+ANP log [M] 
log [M] 
*
**
**
GAPDH
- 6     - 7     -8
Co TNF   ANP  TNF+ANP log[M]
MCP-1
++
RESULTS 
 98
performed, each. Histograms show densitometric evaluation of signal intensities normalized on 
GAPDH and are expressed as percentage of values for TNF-α treatment only. Data show mean ± 
S.E.M. of four independent experiments from different cell preparations. ** p<0.01 and * p<0.05 
represent significant differences compared to the values seen in TNF-α-activated cells. ++ p<0.01 
represents significant differences compared to the values seen in control cells.  
 
3.3.5 Causal relationship between MKP-1-induced inactivation of 
p38 MAPK and reduced MCP-1 expression by ANP 
 
The RT-PCR experiments suggest a transcriptional regulation of the ANP effects on 
TNF-α-induced MCP-1 expression. The p38 MAPK is known to play a pivotal role in 
the transcriptional regulation of MCP-1 expression. Since it is reported under 3.2 that 
ANP is able to inhibit TNF-α-induced phosphorylation of p38 MAPK via induction of 
MKP-1 we aimed to clarify a role for MKP-1 in the observed inhibition of MCP-1 
expression by ANP.  
 
HUVEC were transfected with either MKP-1 antisense or sense phosphorothioate-
modified oligonucleotides. The functionality of the antisense experiment was 
examined by showing MKP-1 induction after antisense treatment in Western blot. 
Indeed, transfection with MKP-1 antisense, but not sense oligonucleotides abolished 
ANP-induced MKP-1 expression (figure 59). 
 
 
figure 58: Blocking of MKP-1 expression by antisense-oligonucleotides  
HUVEC were transfected with antisense or sense MKP-1 oligonucleotides for 3 h or treated with 
transfection reagent without addition of DNA for the respective time (Co). After addition of fresh 
medium, cells were either left untreated or stimulated with ANP (10-6 mol/L; 30 or 60 min). Western 
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blot for MKP-1 was performed as described under Materials and methods. Data show one 
representative out of two independent experiments. Histogram shows densitometric evaluation of two 
independent experiments and represent mean ± S.E.M. whereby values of TNF-α treatment were set 
as 100%. *** p<0.001 represent significant differences from values in control cells.  
 
As demonstrated by figure 59 transfection with MKP-1 antisense, but not sense 
oligonucleotides abrogated the inhibitory effect of ANP on MCP-1 expression. These 
data provided a causal relationship between ANP-mediated induction of MKP-1 and 
inhibition of TNF-α-induced expression of MCP-1 by ANP, suggesting a role for p38 
MAPK in the signal transduction pathway. 
 
 
 
figure 59: Blocking of MCP-1 expression by MKP-1 antisense-oligonucleotides  
HUVEC were transfected with antisense or sense MKP-1 oligonucleotides for 3 h or treated with 
transfection reagent without addition of DNA for the respective time (Co). After addition of fresh 
medium, cells were either left untreated or stimulated with TNF-α (10 ng/ml; 6 h) in presence or 
absence of ANP (10-6 mol/L), which was added to the cells 30 min before TNF-α. ELISA for MCP-1 
was performed as described under Materials and methods. Histogram shows densitometric 
evaluation of three independent ELISA experiments and represents mean ± S.E.M. whereby values of 
TNF-α treatment were set as 100%. ** p<0.01 and *** p<0.001 represent significant difference from 
values in TNF-α-activated cells.  
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4 DISCUSSION

4.1 ADHESION MOLECULES  
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4.1 Adhesion molecules 
4.1.1 ANP inhibits TNF-α-induced expression of adhesion 
molecules due to IκB induction 
 
The recruitment of leukocytes into infected tissue is part of the immune defense 
against external pathogenes. However, an excessive diapedesis of leukocytes to the 
damaged tissue represents a central step in the development of inflammatory 
conditions. In this context the adhesive properties of the endothelium play a crucial 
role and cellular adhesion molecules, such as ICAM-1, VCAM-1, and E-selectin are 
critically upregulated by several stimuli (Gimbrone, Jr. et al. 1997). The inflammatory 
cytokine TNF-α has been shown to modulate the expression of cell adhesion 
molecules. The hypothesis of the first section of the present work was that ANP might 
influence the TNF-α-induced expression of CAM.  
 
4.1.1.1 ANP inhibits expression of ICAM-1 and E-selectin 
 
The results of the present work demonstrated that ANP inhibits a crucial step in the 
pathogenesis of inflammatory states, the expression of CAM. Interestingly, ANP dose-
dependently only affected the expression of ICAM-1 and E-selectin mRNA and 
protein levels, whereas it showed no effect on VCAM-1 expression. These results may 
not surprise taking into account the knowledge about the transcriptional regulation of 
the three CAM. The proinflammatory transcription factor NF-κB has been identified to 
be a key component of the cytokine-inducible expression of ICAM-1 and E-selectin 
(Collins et al. 1995). Despite the knowledge that NF-κB is also involved in regulation 
of VCAM-1 expression, VCAM-1 has previously been shown to be regulated via 
pathways including other proinflammatory transcription factors besides NF-κB, too 
(Lawson et al. 1999). The regulatory regions of the VCAM-1 gene are composed of 
multiple binding elements, which are recognized by a large number of transcription 
factors. The cytokine-induced transcriptional enhancer in the VCAM-1 promoter 
requires combinatorial interactions of NF-κB with other nuclear activators, such as 
stimulatory protein-1, interferon regulatory factor-1, and activator protein-1 (Neish et 
al. 1995a; Neish et al. 1995b; Ahmad et al. 1998). Considering these facts the 
transcriptional regulation of VCAM-1 can not solely be connected to the 
transcriptional activity of NF-κB. 
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4.1.1.2 cGMP-mediated inhibition of CAM expression 
 
ANP is known to mediate most of its cardiovascular and renal effects through 
interaction with the guanylyl-cyclase-coupled natriuretic peptide A-receptor, NPR-A, 
via cGMP as second messenger (Levin et al. 1998). However, ANP has also been 
shown to act through binding the non-guanylyl-cyclase-linked natriuretic peptide 
receptor (NPR-C) (Levin 1993). Taking these facts into account it seemed to be 
important to clarify the receptor specificity of the observed ANP effects. The use of 
the NPR-A antagonist, HS-142-1, the cell permeable cGMP analogue, 8-Br-cGMP, 
and the specific NPR-C agonist cANF, indicate that the inhibitory action of ANP on 
CAM expression is mediated via cGMP. The NPR-A antagonist HS-142-1 abrogated, 
whereas the cGMP analogue 8-Br-cGMP mimicked the effect of ANP on CAM 
expression. Moreover, the specific NPR-C agonist cANF had no influence on TNF-α-
induced CAM expression. Interestingly, CNP, a specific ligand for the other guanylyl-
cyclase-coupled receptor, NPR-B, also showed inhibitory action on CAM.  
cGMP has been described before to attenuate hypoxia/reoxygenation-mediated 
VCAM-1 expression in HUVEC (Collard et al. 1999). However, cGMP analogues 
have also been shown not to interfere with CAM expression induced by TNF-α 
(Spiecker et al. 1998) or other cytokines in human saphenous vein endothelial cells 
(De Caterina et al. 1995) or by IL-1β in HUVEC (Takahashi et al. 1996). These 
contradictory observations might reflect cell type-, species-, and stimulus-dependent 
differences in the regulation of CAM expression. 
 
4.1.1.3 cGMP-mediated inhibition of NF-κB activation 
 
The proinflammatory transcription factor NF-κB is recognized as a ubiquitously 
expressed transcription factor. Upon stimulation NF-κB is rapidly activated and 
regulates the expression of a wide variety of genes, including genes coding for cell 
adhesion molecules (ICAM-1 and E-selectin) and chemokines (MCP-1). Due to the 
central role of NF-κB in the regulation of CAM expression, the effects of ANP on 
TNF-α-induced DNA binding activity of NF-κB were assessed. The results of the 
present work show an attenuated TNF-α-induced activation of NF-κB in endothelial 
cells upon pretreatment with ANP. Interestingly, the specific ligand for NPR-B, CNP, 
also showed this inhibitory property. These observations suggested a role for cGMP in 
regulating NF-κB activation. In fact the use of the cell permeable cGMP analogue 
8-Br-cGMP, and the specific NPR-C agonist cANF, confirmed that the inhibitory 
action of ANP on TNF-α-induced activation of NF-κB is mediated via cGMP: The 
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cGMP analogue 8-Br-cGMP mimicked the effect of ANP and CNP, whereas the 
specific NPR-C agonist cANF had no influence on TNF-α-induced NF-κB DNA-
binding activity. These data provide evidence that ANP and CNP mediate their NF-κB 
inhibiting action via the guanylyl-cyclase-coupled receptors NPR-A and NPR-B. 
Previous works communicated the inhibitory action of ANP on NF-κB in LPS-
stimulated macrophages and reperfused rat livers (Kiemer and Vollmar 1998; Kiemer 
et al., 2000b). Tsukagoshi and coworkers were also able to show a decreased NF-κB 
DNA-binding activity by ANP in IFN-γ-stimulated macrophages (Tsukagoshi et al. 
2001). Our observations are additionally supported by reports of other research groups 
that demonstrated an attenuated activation of NF-κB by cGMP (Collard et al. 1999; 
Ghiso et al. 1999).  
 
4.1.1.4 ANP induces expression of IκB-α and -ε 
 
The activation of NF-κB is known to be regulated by its cytoplasmic inhibitor IκB 
(Ghosh et al. 1998). In unstimulated cells, inhibitory protein IκB binds NF-κB and 
masks its nuclear localization signal, thus retaining it in the cytoplasm (Ghosh et al. 
1998). IκB is a member of a large family of inhibitory molecules that have been 
identified in the last years existing as IκB-α, -β, -ε, and -γ isoforms. To date the best 
characterized IκB is IκB-α, because it was the first identified inhibitor of NF-κB 
(Ghosh et al. 1998). 
As mentioned above, other works demonstrate the inhibitory action of ANP on NF-κB 
in other cell systems. However, the mechanisms involved in this inhibitory action of 
ANP have been completely unknown (Kiemer and Vollmar 1998; Kiemer et al. 2000b; 
Kiemer and Vollmar 2001b; Tsukagoshi et al. 2001). The data presented here provide 
substantial information about the underlying mechanisms involving the induction of 
the IκB isoforms for the first time. This induction of IκB is demonstrated to be 
mediated most likely via a transcriptional regulation, as shown by RT-PCR and the use 
of the transcription inhibitor, actinomycin D. These data are supported by the fact that 
other endogenous substances, such as glucocorticoids (Costas et al. 2000), IL-17 
(Kehlen et al. 1999), and TGF-β1 (Azuma et al. 1999), were also described to 
attenuate NF-κB activation via this pathway. Interestingly, ANP specifically induces 
expression of IκB-α and -ε without increasing IκB-β expression. However, the 
specific regulation of IκB isoforms and the individual relevance is not well-understood 
and current reports are rather rare. Bourke et al. for instance reported IκB-β as the 
crucial inhibitor of NF-κB translocation in glial cells (Bourke et al. 2000). This 
observation is supported by Ghosh and coworkers who describe IκB-β but not IκB-α 
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as the classical cytoplasmic inhibitor of NF-κB in mouse endothelial fibroblast cells. 
Additionally, one work suggests that IκB-ε might be specifically involved in the 
expression of ICAM-1 (Spiecker et al. 2000). These facts may reflect the complexity 
of the regulatory pathway of NF-κB activity by the different IκB isoforms. Moreover, 
species and cell-type seem to play a pivotal role in the regulation of different IκB 
isoforms. 
 
4.1.1.5 ANP induces basal NF-κB activation 
 
Due to the observation that ANP is able to induce IκB isoforms the question came up 
how this transcriptional induction of IκB is regulated. In the present work it could be 
demonstrated that ANP significantly increased basal NF-κB activation. Due to the fact 
that the transcription of IκB is known to be mainly regulated by NF-κB (Read et al. 
1994), this basal activation of NF-κB is suggested to represent a crucial step in 
inhibition of later TNF-α-induced NF-κB activation. This supposition is confirmed by 
other groups. For example, De Martin and coworkers showed that the upregulation of 
IκB-α, as the inhibitor protein of NF-κB, is kind of an autoregulatory loop of NF-κB 
activity by an autocrine fashion (De Martin et al. 2000). The activation of NF-κB by 
ANP has very recently been shown in a model of cardiac ischemia (Izumi et al. 2001) 
and therefore supports our observation. In addition to the well-known pathway of IκB 
regulation by NF-κB it has recently been shown that induction of IκB occurs as a 
response to heat shock, suggesting IκB as a heat shock protein (DeMeester et al. 
1997). In this context it is interesting to note that ANP treatment has been shown to 
exert a heat shock response-like state in livers (Kiemer et al. 2002a). However, the 
roles of specific IκB isoforms in regulating NF-κB activity, and being regulated by 
NF-κB in endothelial cells are not yet defined. 
 
4.1.2 Influence of ANP on AP-1 
 
Activator protein-1 (AP-1) is an important transcription factor known to play a key 
role in cellular proliferation, differentiation, and in inflammatory processes (Rahman 
and MacNee 1998). In order to characterize the specificity of the observed inhibitory 
potential of ANP on TNF-α-induced NF-κB DNA-binding activity, effects of ANP on 
AP-1 were investigated in the present work.  
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4.1.2.1 ANP had no effect on TNF-α-induced AP-1 DNA-binding activity 
 
The results showed that ANP had no effect on the TNF-α-induced AP-1 DNA binding 
activity. In contrast to this result ANP has previously been shown to possess an 
inhibitory potential on AP-1 DNA-binding activity. This was demonstrated for LPS-
activated murine macrophages (Kiemer et al. 2000a) and reperfused rat livers (Kiemer 
et al. 2000b). These different observations may reflect cell-type, -species, and stimuli-
dependent differences in the action of ANP. 
These data show that ANP is not an overall inhibitor of TNF-α-induced signaling 
pathways in endothelial cells but suggests a certain specificity of the inhibitory action 
of ANP on the NF-κB DNA-binding activity.  
 
4.1.2.2 ANP-induced DNA-binding activity of AP-1 
 
Interestingly, the results of the present work concerning the effects of ANP on basal 
AP-1 DNA-binding activity indicate that ANP is able to increase the basal activity of 
AP-1. These first observations were confirmed by the use of an inhibitor of AP-1 
transcription, U0126, which was able to completely attenuate the ANP induced AP-1 
DNA-binding activity. These data are supported by reports that cGMP induces AP-1- 
related transcriptions (Pilz et al. 1995). AP-1 is described as the main transcription 
factor involved in the induction of the cytoprotective HSP32/HO-1 (Immenschuh et al. 
1998). Since AP-1 plays a key role in proliferation, differentiation, and transcription of 
cytoprotective genes, e.g. HO-1, the observed effects may have an impact on 
cytoprotective properties exerted by ANP (Kiemer et al. 2002a). The role of ANP 
mediated AP-1 activation in endothelial cells will be further characterized by Nicole 
Bildners doctoral thesis.  
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4.2 Cytoskeleton 
4.2.1 ANP reduces TNF-α-induced stress fiber formation and 
endothelial permeability via induction of MKP-1 
 
The TNF-α-induced increase in vascular permeability is commonly attributed to the 
reorganization of F-actin filaments into stress fibers followed by contraction of cells 
and formation of intercellular gaps (Brett et al. 1989; Lum and Malik 1996; van 
Hinsbergh 1997; Wojciak-Stothard et al. 1998). The underlying molecular 
mechanisms of a potential protective action of ANP on the detrimental action of TNF-
α on the endothelial cytoskeleton are not completely understood. In this context the 
second section of the present work aimed to clarify the effects of ANP on TNF-α-
mediated pathophysiological cytoskeleton changes. Potentially involved signal 
transduction mediators (e.g. p38 MAPK, HSP27, MKK 3/6, and MAPK-phosphatase-
1) were investigated in order to clarify the molecular mechanism of the observed 
effects. 
 
4.2.1.1 ANP reduces TNF-α-induced changes in endothelial morphology, 
cytoskeleton, and function 
 
The present work provides evidence that the cardiovascular hormone ANP can 
abrogate TNF-α-induced changes in endothelial morphology and macromolecule 
permeability. These inhibitory properties of ANP were shown to be mediated via 
cGMP. The observed effects of ANP are supported by a paper showing a protective 
effect of ANP against lysophosphatidylcholine-induced endothelial dysfunction 
(Murohara et al. 1999). Moreover, a cGMP-dependent inhibition of thrombin induced 
increase in permeability has been described in bovine aortic endothelial cells (Lofton 
et al. 1990). Furthermore, there exist in vivo data which suggest that cGMP can have 
both positive and negative effects on endothelial permeability (van Hinsbergh 1997). 
For instance one work demonstrates that cGMP-elevating agents cause a decrease of 
vascular leakage after oxidative damage in bovine aortic endothelial cells and perfused 
rabbit lungs in the lung circulation (Lofton et al. 1991), whereas in the peripheral 
circulation cGMP-elevating agents worsen the vascular leakage (Zimmerman et al. 
1990; Lofton et al. 1991). These different observations may demonstrate cell-type-, 
species-, and stimuli-dependent differences in the action of ANP, respectively cGMP, 
on cytoskeleton and permeability changes. Since TNF-α plays a pivotal role in 
formation of atheromatous plaques, the ability of ANP to abrogate TNF-α-induced 
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increase in permeability is of special interest suggesting an antiatherogenic action for 
this cardiovascular hormone. The following sections elucidate the mechanisms 
underlying this protective action of ANP on TNF-α-exposed endothelium. 
 
4.2.1.2 ANP inhibits TNF-α-induced actin polymerization via cGMP 
 
The fact that ANP is able to abolish TNF-α-induced morphological changes and 
increased macromolecule permeability combined with the knowledge that increased 
permeability is closely associated with increased formation of F-actin (Brett et al. 
1989; Lum and Malik 1996; van Hinsbergh 1997; Wojciak-Stothard et al. 1998) and 
the development of stress fibers (Brett et al. 1989; van Hinsbergh 1997; Wojciak-
Stothard et al. 1998) leads to investigations that focus on effects of ANP on actin 
polymerization and the subsequent development of F-actin stress fibers.  
The results showed no effect of ANP on basal F-actin content in endothelial cells 
whereas TNF-α-induced formation of F-actin was dose-dependently reduced by ANP. 
The effects of ANP on F-actin content could be confirmed by microscopic 
investigations using a specific F-actin staining dye (rhodamin phalloidin). It was 
indeed possible to show a reduced formation of F-actin stress fibers upon pretreatment 
with ANP. In order to clarify the receptor specificity of the observed inhibitory action 
of ANP on TNF-α-induced F-actin content and stress fiber formation, NPR-A second 
messenger analogue 8-Br-cGMP was tested for its effect on these parameters. The 
results clearly indicate the involvement of cGMP in the effects exerted by ANP, since 
8-Br-cGMP at least partially mimicked the effects. So far little information exists on 
actions of ANP on F-actin content and stress fiber formation. Only a single paper by 
Sharma and coworkers demonstrated that incubation of glomerular epithelial cells with 
ANP resulted in an apparent disassembly of stress fibers mediated via cGMP (Sharma 
et al. 1992).  
These results of reduced TNF-α-induced F-actin polymerization by ANP seemed to be 
part of a potential mechanism by which ANP can regulate TNF-α-induced changes in 
endothelial cell morphology and macromolecule permeability. The following studies 
aimed to clarify the signal transduction pathway underlying the observed effects. 
 
4.2.1.3 ANP inhibits p38 MAPK activation via induction of MKP-1 
 
In the present work it is reported for the first time that ANP inhibits TNF-α-induced 
phosphorylation of the actin capping protein HSP27. This inhibition of the HSP27 
phosphorylation by ANP is suggested as the crucial step in the signal transduction 
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mechanism underlying the inhibitory property of ANP on TNF-α-induced endothelial 
cell cytoskeleton changes. HSP27 has been closely associated with the regulation of 
actin polymerization (Landry and Huot 1995; Razandi et al. 2000) which represents a 
key step in the formation of stress fibers (Wojciak-Stothard et al. 1998). The function 
of HSP27 in regulating the actin cytoskeleton has indeed been shown to be dependent 
on the phosphorylation state of this protein (Lavoie et al. 1993).  
Diverse physiological stimuli, such as cytokines have been shown to dramatically 
increase the phosphorylation of HSP27 (Gaestel et al. 1991). The phosphorylation of 
HSP27 is known to be catalyzed by a member of the family of mitogen activated 
protein kinases (MAPK), the p38 MAPK (Kyriakis and Avruch 1996). The present 
work shows an inhibition of TNF-α-induced activation of p38 MAPK by ANP, 
suggested to be the mechanism responsible for the inhibited phosphorylation of HSP27 
by ANP. The observation of a decreased activation of p38 MAPK by ANP has been 
described in the literature before: the inhibitory action of ANP on TNF-α production 
was demonstrated to be mediated via an attenuation of LPS-induced activation of p38 
MAPK in macrophages (Tsukagoshi et al. 2001). Moreover, ANP was shown to 
reduce VEGF-induced activation of p38 MAPK in bovine aortic endothelial cells 
(Pedram et al. 2001). These papers support our observation of ANP as an inhibitor of 
p38 MAPK. However, no information exists on the ANP-induced signaling leading to 
suppressed p38 activity.  
In order to clarify the mechanism which is responsible for suppressed p38 
phosphorylation two possible targets for ANP were investigated. On the one hand p38 
MAPK is known to be regulated by its upstream kinase MKK3/6 (Herlaar and Brown 
1999). On the other hand dual-specific MAPK phosphatases (MKP) are known to 
dephosphorylate and therefore deactivate MAPK. From the known MKP, MKP-1 
(CL100) has been shown to be specifically responsible for the dephosphorylation of 
p38 (Chen et al. 2001), which could neither be shown for MKP-2 (Chu et al. 1996) nor 
MKP-3 (Nichols et al. 2000).  
Interestingly, the results of the present work indicate that ANP does not affect the 
activation of MKK3/6 upstream of p38 MAPK, but induces MKP-1 via an elevation of 
MKP-1 mRNA. MKP-1 mRNA was induced by ANP after only 20 min and moreover 
the protein levels were elevated after only 30 min. These observations of MKP-1 as an 
immediate early gene product were supported by others, since ANP has been described 
to induce MKP-1 mRNA after 30 min in mesangial cells (Sugimoto et al. 1996) and 
MKP-1 protein after only 30 min in renal tubular cells (Hannken et al. 2001) as well. 
Furthermore, other stimuli than ANP were reported to induce MKP-1 mRNA in less 
than 30 min. For instance Metzler and coworkers showed an increased MKP-1 
expression after only 20 min treatment with arachidonic acid in VSMC (Metzler et al. 
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1998). The fact that the human MKP-1 gene (CL100) contains one AP-1 binding site 
(Kwak et al. 1994) and the discussed data concerning AP-1 activation by ANP led to 
the hypothesis that ANP may induce MKP-1 via activation of this AP-1 site. Although 
ANP has been reported before to induce MKP-1 in other cell systems, it was not 
clarified whether induction of MKP-1 by ANP is causally linked to the observed 
inhibition of p38 MAPK as suggested by our experiments. To investigate this causal 
link seemed essential since there exist data that indicate that an increased MKP-1 
expression does not inevitably contribute to the deactivation of MAPK (Wu et al. 
1994; Jeon et al. 1998). Therefore we performed MKP-1 antisense experiments to 
clarify the causal role of MKP-1 induction in ANP-mediated p38 MAPK inhibition. 
MKP-1 antisense but not sense oligonucleotides abrogated the inhibitory effect of 
ANP on p38 MAPK activation. This fact demonstrates for the first time that the rapid 
transcriptional up-regulation of MKP-1 by ANP is necessary for early inhibition of 
TNF-α-induced p38 activation in human endothelial cells. 
 
4.2.1.4 Causal relationship between the MAPK pathway, F-actin 
polymerization, and macromolecule permeability 
 
After characterization of the signaling pathway leading to attenuated p38 MAPK 
activation, however, the inhibitory action of ANP on the TNF-α-induced p38 MAPK 
activation was not causally linked to the observed effects of ANP on F-actin 
polymerization and macromolecule permeability. In order to elucidate the potential 
involvement of the p38 MAPK signaling pathway in ANP-mediated effects on 
cytoskeleton and permeability changes, the p38 MAPK inhibitor, SB203580, was 
tested for its effects on TNF-α-induced F-actin polymerization and increased 
macromolecule permeability. As shown by the results SB203580 abrogates both F-
actin polymerization as well as TNF-α-induced elevation of macromolecule 
permeability. These facts suggest a direct involvement of p38 MAPK in both signaling 
pathways and causally connect TNF-α-induced alterations in HUVEC with the p38 
MAPK signaling cascade. Moreover and importantly, it is shown here that ANP 
counteracts the TNF-α-induced formation of stress fibers and increased permeability 
by inhibiting p38 MAPK signaling. 
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4.3 Monocyte chemoattractant protein MCP-1 
 
MCP-1 has been shown to play a key role in inflammation. In this context it has been 
demonstrated to be critically involved in the pathogenesis of atherosclerosis (Reape 
and Groot 1999) and it is highly recognized to be expressed in human atherosclerotic 
lesions (Nelken et al. 1991; Yla-Herttuala et al. 1991).  
In the present study it is demonstrate that the cardiovascular hormone ANP is able to 
suppress the TNF-α-induced expression of MCP-1 via induction of MKP-1 in 
endothelial cells. Thus, this inhibitory action of ANP on MCP-1 secretion in human 
endothelial cells might contribute to an antiinflammatory and especially 
antiatherogenic potential of this cardiovascular hormone. 
 
4.3.1 cGMP-mediated inhibition of TNF-α-induced MCP-1 
release 
 
The results presented here indicate that the inhibitory action of ANP on TNF-α-
induced MCP-1 expression is mediated via cGMP. 8-Br-cGMP mimicked the effect of 
ANP on MCP-1 release and CNP, the ligand for the other guanylyl-cyclase-coupled 
receptor, NPR-B, also shows inhibitory action on MCP-1 secretion. Furthermore the 
specific NPR-C agonist cANF did not affect TNF-α-induced MCP-1 secretion 
confirming the role for a guanylyl-cyclase-dependent pathway. To our knowledge the 
regulatory action of cGMP on TNF-α-induced MCP-1 release has yet been comletely 
unknown. Therefore our data are the first to report the inhibitory action of cGMP on 
TNF-α-induced MCP-1. 
More information exists on the regulatory mechanisms of MCP-1 expression in 
endothelial cells induced by stimuli other than TNF-α. For instance Chien and 
coworkers reported that cGMP plays no role in the regulation of mechanical strain 
stress-induced MCP-1 expression in HUVEC (Wang et al. 1995). Another report by 
Okada et al. showed no influence of cGMP on cyclic stretch-induced upregulation of 
MCP-1 in HUVEC (Okada et al. 1998). These contradictory data may reflect 
especially stimulus- dependent differences in MCP-1 regulation. 
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4.3.2 Modulation of TNF-α-induced MCP-1 release by NO 
 
The observation that the ANP-mediated inhibition of TNF-α-induced MCP-1 secretion 
is most likely regulated via guanylyl-cyclase-dependent pathways led us to focus on an 
important activator of cGMP release, NO. NO activates the soluble guanylyl-cyclase 
and thereby increases intracellular cGMP. Therefore, we were interested in the effect 
of NO-modulating substances on TNF-α-induced MCP-1 secretion. The data 
presented here show indeed an attenuated TNF-α-induced MCP-1 release in HUVEC 
pre-treated with the NO-donor GSNO. This result confirms our hypothesis of a signal 
transduction pathway involving cGMP as second messenger mediating an inhibitory 
action on MCP-1 induction. To our knowledge so far nothing is known about an 
inhibitory property of NO on TNF-α-induced MCP-1 expression in HUVEC. 
Therefore the data presented here show for the first time that NO is able to inhibit 
TNF-α-induced MCP-1 expression.  
 
4.3.3 Regulation of basal MCP-1 production 
 
Interstingly, NO has been recognized to regulate basal MCP-1 expression in HUVEC. 
Zeiher et al. report a NO-dependent decrease in basal MCP-1 expression (Zeiher et al. 
1995). However, in our experimental settings the NO-Donor GSNO did not affect 
basal MCP-1 release. This discrepance of our data to the literature may be due to the 
use of different NO-donors and stimulation times.  
8-Bromo-cGMP did not affect basal MCP-1 expression in our experiments excluding a 
role for cGMP in basal regulation of MCP-1. These observations are supported by the 
group of Zeiher who demonstrated that elevation of endothelial cGMP levels have no 
effect on basal MCP-1 expression (Zeiher et al. 1995).  
Interstingly, ANP and the specific NPR-C agonist cANF increased basal MCP-1 
secretion. The activation of NPR-C by ANP was shown to result in an inhibition of 
adenylyl-cyclase and decreased cAMP levels in endothelial cells (Hu et al. 1992). 
Therefore our data strongly suggest a role for NPR-C and cAMP in the signal 
transduction pathway of basal MCP-1 expression. Contradictory to these results some 
groups describe an increased MCP-1 expression as result of increased cAMP levels. 
For example leptin was shown to clearly activate MCP-1 secretion via activation of the 
cAMP-dependend PKA in bovine aortic endothelial cells (Yamagishi et al. 2001). This 
work is supported by two other works demonstrating that an increased level of 
intracellular cAMP induces MCP-1 expression in human endothelial cells (Shyy et al. 
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1993; Zeiher et al. 1995). These different data may reflect stimulus- and cell-type-
dependent differences in basal MCP-1 release.  
Nevertheless a regulatory role for NPR-C and cAMP in the secretion of basal MCP-1 
in endothelial cells has yet not been described.  
Since endothelial cells themselves represent a source of NO production (Preli et al. 
2002) we aimed to exclude a potential role for TNF-α-induced endogenous NO 
production in our cell system. Since the NOS inhibitor L-NNA did not affect TNF-α-
induced MCP-1 release, endogenous NO production appeares not to be involved in 
regulating MCP-1 induction. 
 
4.3.4 Molecular mechanism of reduced TNF-α-induced MCP-1 
expression by ANP 
 
The inhibitory action of ANP on MCP-1 release is regulated most likely on a 
transcriptional level due to the observed decrease in TNF-α-induced MCP-1 mRNA 
levels. The transcriptional regulation of MCP-1 expression has been increasingly 
recognized to be mediated via the p38 MAPK pathway (Goebeler et al. 2001; Marin et 
al. 2001). For instance Goebeler and coworkers recently reported the involvement of 
p38 MAPK in TNF-α-induced MCP-1 expression in endothelial cells(Goebeler et al. 
1999). The group of Nakamura showed an inhibitory action of circulating thioredoxin 
on LPS-induced MCP-1 expression via suppressed p38 phosphorylation (Nakamura et 
al. 2001).  
As it is demonstrated in the present work, ANP inhibits TNF-α-induced p38 MAPK 
activation in HUVEC. We show that this inhibitory action of ANP was mediated via 
an early transcriptional induction of MKP-1 by ANP (Kiemer et al. 2 A.D.). 
Considering these facts we were interested in the causal relationship between MKP-1 
induction by ANP and the observed inhibition of MCP-1 release. The data presented 
here show indeed a causal role for MKP-1 induction in ANP-mediated MCP-1 
inhibition since MKP-1 antisense but not sense oligonucleotides abrogated the 
inhibitory effect of ANP on TNF-α-induced MCP-1 expression. These results causally 
connect ANP-mediated inhibition of TNF-α-induced MCP-1 expression to the p38 
MAPK pathway. 
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5.1 Summary 
 
The present work deals with the inhibitory action of ANP on TNF-α-induced 
expression of adhesion molecules (ICAM-1, VCAM-1, E-selectin), chemokines 
(MCP-1), and cytoskeleton changes in human endothelial cells.  
 
5.1.1 Effect of ANP on TNF-α-induced CAM expression 
 
The following diagram shows a schematic outdraw of the summerized results of the 
first part of the present work. 
 
figure 1 summary: schematic diagram of the signal transduction pathways clarified by the first 
section of the present work 
 
It has been shown before that TNF-α increases the expression of cell adhesion 
molecules E-selectin and ICAM-1 via activation of the transcription factor NF-κB.  
We could show that ANP is able to inhibit the activation of NF-κB via binding its 
guanylyl-cyclase-coupled NPR-A and -B receptor. We could further elucidate the 
molecular mechanism leading to the inhibition of NF-κB activation by ANP. ANP was 
shown to transcriptionally activate the expression of IκB isoforms. In consequence of 
the ANP mediated inhibition of NF-κB DNA-binding activity we could demonstrate 
an attenuated surface expression of E-selectin and ICAM-1. 
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5.1.2 Effect of ANP on TNF-α-induced cytoskeleton and perme-
ability changes 
 
The following figure shows an outdraw of the summerized results of the second part of 
the present work. 
 
 
figure 2 summary: schematic diagram of the signal transduction pathways clarified by the second 
section of the present work 
 
TNF-α has been shown to induce changes in cytoskeleton and macromolecule 
permeability of endothelial cells.  
We have shown here for the first time that ANP is able to abrogate both TNF-α-
induced effects via its guanylyl-cyclase-coupled NPR-A receptor. Moreover, ANP was 
shown to reduce TNF-α-induced F-actin polymerization and stress fiber formation via 
the inhibition of p38 MAPK and its downstream target HSP27. Furthermore we could 
report here for the first time a decrease in TNF-α-induced macromolecule permeability 
by ANP. The deactivation of p38 MAPK was demonstrated to be mediated via a 
significant transcriptional induction of the MKP-1 by ANP.  
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5.1.3 Effect of ANP on TNF-α-induced MCP-1 expression 
 
The results of the third part of the present work are summerized in figure 3. 
 
 
figure 3 summary: schematic diagram of the signal transduction pathways clarified by the first and 
third section of the present work 
 
It is known that TNF-α induces the release of MCP-1 during inflammatory processes 
via influencing the transcription factor NF-κB and the p38 MAPK pathway. 
We could report here for the first time a decreased TNF-α-induced MCP-1 expression 
by treatment of endothelial cells with ANP. The observed ANP effect was shown to be 
mediated via the particulate guanylyl-cyclase-coupled NPR. Furthermore we show that 
trancriptional induction of MKP-1 by ANP is essential for inhibition of TNF-α-
induced MCP-1 expression by ANP.  
 
In summary the data presented here provides evidence that ANP is able to preserve the 
structure and function of endothelial cells. These observations are of special 
importance because there is clear evidence that endothelial cell dysfunction is the 
cause for many acute and chronic vascular diseases (Biegelsen and Loscalzo 1999). 
The potency of an endogenous compound, i.e. ANP, to protect against such endothelial 
dysfunction points to an antiinflammatory and antiatherogenic potential of this 
cardiovascular hormone. 
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6.1 Abbreviations 
A  Ampere 
AB  Antibody 
ANP  Atrial natriuretic peptid 
AP-1/2 Activator protein 1/2 
APS  Ammonium persulfate 
ATP  Adenosine-5`-triphosphate 
BNP  Brain natriuretic peptid 
bp  Basepair 
Bq  Bequerel 
BSA  Bovine serum albumine 
CAM  Cell Adhesion Molecule 
cAMP  cyclic Adenosine-5`-monophosphate 
cDNA  complementary DNA 
cGMP  Cyclic Guanosin-5´-monophosphate 
cpm  Counts per minute 
cRNA  complementary RNA 
Ci  Curie (1 Ci=3.7x1010 Bequerel)   
CNP  C-type natriuretic peptide 
Co  Control 
Da  Dalton 
dATP  2`-Desoxyadenosine-5`-triphosphate 
dCTP  2`-Desoxycytosine-5`-triphosphate 
dGTP  2`-Desoxyguanosine-5`-triphosphate 
DMSO Dimethylsulfoxide 
DNA  Desoxyribonucleic acid 
dNTP  Desoxynucleosidtriphosphate 
DTT  Dithioerythriol 
ECL  Enhanced Chemoluminescence reagent 
EDTA Ethylene diamine-N,N,N´,N´ tetra acid 
EGTA Bis(aminoehyl)glycolether-N,N,N´,N´-tetra acid 
EMSA Electrophoretic mobility shift assay 
EtBr  Ethidium bromide 
EtOH  Ethanol 
FITC  Fluoresceinisothiocyanate 
FCS  Fetal calf serum 
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GTP  Guanosin-5`-triphosphate 
h  Hour 
HUVEC Human Umbilical Vein Endothelial Cells 
ICAM  Intracellular Cell Adhesion Molecule 
IκB (α-ε) Inhibitory protein (α-ε) 
kDa  kilo Dalton 
L  Liter 
m  Milli (10-3) 
M  Molar 
MeOH Methanol 
µ  Micro (10-6) 
min  Minute  
MCP-1 Monocyte chemoattractant protein 
mRNA messenger Ribonucleinic acid 
% (m/v) mass per volume per cent 
n  nano (10-9) 
NF-κB Nuclear Factor κB 
NP  Natriuretic Peptides 
NPR  Natriuretic Peptide Receptor 
NTP  ATP, CTP, GTP, or TTP 
OD  Optical Density 
PAA  Polyacrylamide 
PAGE  Polyacrylamide-gel electrophoresis 
PBS  Phosphate buffered saline solution 
PCR  Polymerase chain reaction 
PMSF  Phenylmethylsulfonylfluoride 
Poly[dIdC] Polydesoxyinosine-desoxycytosine 
RNA  Ribonucleinic acid 
RNase Ribonuclease 
rpm  Rotations per minute 
RT  Room temperature 
sec  Second 
SEM  Standard error of the mean value 
SDS  Sodium dodecyl sulfate 
SMC  Smooth muscle cells 
STE  Sodium chloride, Tris, EDTA buffer 
TAE  Tris, acetate, EDTA buffer 
TBE  Tris, borate, EDTA buffer with Triton X-100 
6.2 ALPHABETICAL ORDER OF COMPANIES  
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TBS-T Phosphate buffered saline solution with Tween 
TE  Tris-EDTA buffer 
TEMED N,N,N´,N´-tetramethylethylendiamine 
TNF-α Tumor necrosis factor alpha 
tot RNA total RNA 
Tris  Tris-hydroxymethyl-aminomethan 
U  Unit 
UTP  Uridine-5`-triphosphate 
V  Volt 
VCAM Vascular Cell Adhesion Molecule 
% (v/v) Volume per volume  
W  Watt 
 
6.2 Alphabetical order of companies 
 
Alexis Biochemicals  (Grünberg, Germany) 
Amersham    (Braunschweig, Germany) 
Beckmann Instruments   (Munich, Germany) 
Becton Dickinson   (San Jose, CY, USA) 
Biochrom     (Berlin, Germany) 
Biometra    (Göttingen, Germany) 
BioRad Laboratories  (Munich, Germany) 
Biosource     (Nivelles, Belgium) 
Bio Whittaker Bioproducts  (Heidelberg, Germany) 
Biozym Diagnostics   (Oldendorf, Germany) 
Calbiochem     (Schwalbach, Germany) 
Carl Roth    (Karlsruhe, Germany) 
Cell Signaling    (Frankfurt/M, Germany) 
Dianova     (Hamburg, Germany) 
Eppendorf    (Maintal, Germany) 
Gibco/BRL    (Eggenstein, Germany) 
Gilson    (Villiers-Le Bel, France) 
Greiner    (Nürtingen, Germany) 
ICN Biomedicals   (Eschwege, Germany) 
Jackson Immunolab   (Hamburg, Germany) 
Merck-Eurolab    (Munich, Germany) 
Millipore     (Eschborn, Germany) 
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Molecular probes   (Göttingen, Germay)  
MWG-biotech   (Ebersberg, Germany) 
NEN      (Cologne, Germany) 
NUNC    (Wiesbaden, Germany 
PAN      (Aidenbach, Germany) 
Peske     (Aindling-Pichl, Germany) 
Pharmacia Biotec   (Heidelberg, Germany) 
Promocell     (Heidelberg, Germany) 
Qiagen    (Hilden, Germany) 
Roche     (Mannheim, Germany) 
Santa Cruz     (Heidelberg, Germany) 
Saxon Biochemicals   (Hannover, Germany) 
Shimadzu    (Duisburg, Germany) 
Schleicher & Schüll   (Dassel, Germany) 
Serotec LTD    (Wiesbaden, Germany) 
Sigma     (Taufkirchen, Germany) 
Stratagene    (Heidelberg, Germany) 
Stressgen     (San Diego, USA) 
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6.3 Publications 
 
Parts of this work are published or are in preparation for publication: 
 
Poster: 
 
Nina C. Weber, Nicole Bildner, Angelika M. Vollmar, Alexandra K. Kiemer, 2002, 
ANP inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via 
induction of IκB. Poster presentation at the 43. Tagung der Deutschen Gesellschaft für 
klinische Pharmakologie und Toxikologie in Mainz. 
 
Alexandra K. Kiemer, Nina C. Weber, Nicole Bildner, Angelika M. Vollmar, 1999, 
ANP verhindert TNF-α-induzierte Veränderungen von Morphologie und Zytoskelett 
in Endothelzellen. Poster presentation at the 7. Tagung für Zell und 
Gewebeschädigung in Weinheim. 
 
Lecture: 
 
Nina C. Weber, Alexandra K. Kiemer, Robert Fürst, Angelika M. Vollmar, 2001, The 
atrial natriuretic peptide reduces TNF-α-induced actin polymerization and 
permeability in endothelial cells. Lecture at the 8. Tagung für Zell und 
Gewebeschädigung in Halle. 
 
Original publications: 
 
Nina C. Weber, Angelika M. Vollmar, Thomas Hartung, Alexandra K. Kiemer, 2002. 
The atrial natriuretic peptide inhibits TNF-α-induced expression of MCP-1 via 
induction of MKP-1. Arteriosc.Throm.Vasc. Biol. Submitted for publication. 
 
Alexandra K. Kiemer, Nina C. Weber, Robert Fürst, Nicole Bildner, Stefanie 
Kulhanek-Heinze , Angelika M. Vollmar, 2002. Inhibition of p38 MAPK activation 
via induction of MKP-1: Atrial Natriuretic Peptide reduces TNF-α-induced actin 
polymerization and endothelial permeability. Circulation Research, May 2002. 
 
Alexandra K. Kiemer, Nina C. Weber, Angelika M. Vollmar, 2002. Induction of IκB: 
Atrial Natriuretic Peptide inhibits endothelial expression of adhesion molecules. Mol. 
Pharmacol. Submitted for publication. 
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Alexandra K. Kiemer, Nicole Bildner, Nina C. Weber, Angelika M. Vollmar, 2002. 
Induction of heme oxygenase-1 (HO-1) by the Atrial Natriuretic Peptide does not 
confer resistance against TNF-α-induced apoptosis in endothelial cells. In preparation. 
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